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Summary 
 
 
During leukemia development malignant cells occupy hematopoietic stem cell niches 
suppressing normal hematopoiesis and infiltrate other sanctuary niches such as the central 
nervous system or the testis. Interactions with the microenvironment are critical for leukemia 
cell survival, but the mechanisms involved in these processes are largely unknown. A better 
understanding of the patterns of intercellular dependence between leukemia and its 
microenvironment will possibly provide new options to improve leukemia treatment.  
 
To identify new pathways that contribute to the leukemia niche function, I established a large 
scale high-content (automated image-based) screening platform using co-cultures of primary 
acute lymphoblastic leukemia cells (ALL) on human mesenchymal stromal cells (MSC). 
Patient samples were expanded by xenotransplantation in immunodeficient mice to generate 
a renewable source of leukemic cells for systematic functional investigation. The 
methodology and analytic pipeline was developed in our laboratory in collaboration with the 
Light Microscopy and Screening Centre of ETH Zurich. We established a robust workflow to 
discriminate viable ALL and stromal cells using a fluorescent dye. Detailed protocols were 
optimized to use this platform for in vitro drug testing and for functional genomic projects. 
 
Based on gene expression and cell surface proteomic data that we had obtained from both 
cellular compartments, I generated a customized siRNA library for 110 candidate genes with 
a potential function in stromal support. Primary ALL cells were seeded on reversely 
transfected MSC cells, and ALL cell viability was assessed after 6 days using the established 
high-content screening platform. From a first screen with three cases with highly resistant 
disease, 20 candidate genes were identified that reproducibly reduced ALL survival in this 
assay. These were validated in 10 different patient samples. Importantly, specific and distinct 
contributions of stromal genes for the survival of individual ALL samples were detected. The 
strongest effects were observed after RNA interference of the vascular endothelial growth 
factor C (VEGFC) or of Basigin (BSG, alias CD147) in a subset of patient samples. 
Dependence from stromal VEGFC predicted sensitivity to two different VEGF receptor kinase 
inhibitors, confirming the patient specific support pattern of stromal VEGFC. Furthermore, the 
Notch and Wnt pathways were identified to play an important role for the support of ALL 
cells, extending experimental data obtained in other model systems of the tumour 
microenvironment or HSC niches. The largest subset of ALL samples was most dependent 
on the expression of BSG on stromal cells. I could show that this multifunctional cell surface 
protein was required to provide metabolic support to a subset of ALL in association with the 
solute carrier family 3 protein, SLC3A2. This protein forms heterodimeric amino acid 
transporters (HAT) on MSCs indicating that amino acid transport of stromal cells is important 
for survival of ALL cells. Leukemic cells are deficient to import cystine, and a subset of 
leukemic cases requires continuous supply of cysteine for de novo glutathione synthesis. We 
could show that the metabolic transport function of amino acids by stromal cells maintains 
glutathione levels and reduces oxidative stress specifically in ALL cells that were dependent 
on stromal BSG/SLC3A2. Indeed, addition of cysteine but not cystine rescued the effect of 
RNA interference with BSG/SLC3A2 in stromal cells.  
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Taken together, I describe the development of a new platform for systematic investigation of 
interactions between primary leukemia and stromal cells. The identification of relevant and 
leukemia-specific pro-survival cues from stromal cells validates this approach. Strong 
interaction patterns such as the one reported here suggest new possibilities for targeted 
therapy provided appropriate biomarkers are developed to select patient cohorts efficiently. 
The platform can also be used for the analysis of anti-leukemic activity of small molecules as 
single agents and in combinations. This work will also constitute the basis for a more 
comprehensive functional genomic screen and will stimulate the development of in vivo 
models. 
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Zusammenfassung 
 
In Leukämien besetzen maligne Krebszellen hämatopoetische Stammzellnischen und 
unterdrücken dort die normale Hämatopoese. Zusätzlich werden weitere schützende 
Nischenumgebungen infiltriert, z.B. im zentralen Nervensystem oder in den Hoden. Die 
spezifischen Wechselwirkungen mit der Umgebung der Nischen sind für das Überleben der 
leukämischen Zellen von entscheidender Bedeutung, die zugrundeliegenden Mechanismen 
sind aber weitestgehend unbekannt. Ein besseres Verständnis der Interaktionen zwischen 
leukämischen Zellen und dem umgebenden Nischengewebe bildet eine Grundlage, um neue 
Wege in der Krebstherapie aufzuzeigen. 
 
Um die Mechanismen zu identifizieren, die zur schützenden Funktion der Nischenumgebung 
beitragen, wurde eine Plattform etabliert, um mit bildgebenden Verfahren Ko-Kulturen von 
primären leukämischen Zellen mit humanen Stromazellen des Knochenmarks automatisiert 
zu evaluieren. Das Patientenmaterial wurde durch Xenotransplantation in immundefizienten 
Mäusen amplifiziert, welches eine erneuerbare Quelle zur systematischen und funktionellen 
Untersuchungen von Leukämiezellen darstellt. Die Methodologie und die analytische 
Auswertung wurde in Zusammenarbeit mit dem Mikroskopie- und Screening-Zentrum der 
ETH Zürich entwickelt. Wir konnten einen robusten Arbeitsablauf etablieren, durch den wir in 
der Lage sind, lebendige leukämische Zellen und Stromazellen in Ko-Kultur mittels eines 
Fluoreszenzfarbstoffes zu unterscheiden. Die Plattform wurde weiterhin hinsichtlich eines 
Einsatzes für in vitro Studien von neuen potentiell anti-leukämischen Substanzen sowie 
funktionelle genomische Analysen optimiert. 
 
Basierend auf Genexpressions- und Zelloberflächenproteom-Daten, die wir von beiden 
Zelltypen generiert haben, wurde eine maßgeschneiderte siRNA-Bibliothek für 110 Kandidat-
Gene erstellt, die für die zellulären Interaktionen zwischen Leukämie- und Stromazellen des 
Knochemarks von Relevanz sein könnten. Primäre Leukämie-Zellen wurden auf MSC-Zellen 
ausgesät, in denen diese Gene mit Hilfe der RNA Interferenz inhibiert worden waren, und die 
Viabilität der Leukämie-Zellen wurde nach 6 Tagen mit der obengenannten Plattform 
evaluiert. In einer ersten Studie mit drei Fällen von hoch-resistenten Leukämien wurden 20 
Kandidat-Gene identifiziert, deren Inhibition reproduzierbar das Überleben der leukämischen 
Zellen verringerten. Diese Effekte wurden in 10 weiteren unterschiedlichen Patientenproben 
validiert. Von Bedeutung ist hierbei, dass spezifische und unterschiedliche Wirkungen dieser 
Stromazell-Gene auf das Überleben der einzelnen Patientenproben nachgewiesen werden 
konnten. Die stärksten Beeinträchtigungen auf das Überleben der leukämischen Zellen 
wurden nach RNA-Interferenz des vaskulären endothelialen Wachstumsfaktors C (VEGFC) 
bzw. Basigin (BSG, Alias CD147) in spezifischen Untergruppen von Patientenproben 
beobachtet. Der Einfluss von VEGFC aus dem Stroma konnte die Empfindlichkeit gegen 
zwei verschiedene VEGF-Rezeptor-Kinase-Hemmer voraussagen, was das Patienten-
spezifische Unterstüzungsmuster weiterhin bestätigt. Darüber hinaus konnte den Notch- und 
Wnt-Signalwegen eine wichtige Rolle bei der Unterstützung des Überlebens der 
leukämischen Zellen zugeschrieben werden. Dies erweitert die experimentellen Daten aus 
anderen Modellsystemen der Tumor-Umgebung oder hämatopoetischen Stammzellnischen. 
Ein Grossteil aller getesteten Zellen war im hohen Maße von der Expression von BSG auf 
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Stromazellen abhängig. Es konnte gezeigt werden, dass dieses multifunktionale 
Zelloberflächenprotein benötigt wird, um metabolische Interaktionen in Verbindung mit dem 
solute carrier family 3-Protein, SLC3A2, aufrecht zu erhalten. SLC3A2 ist Bestandteil von 
heterodimeren Aminosäuretransporter (HAT) auf der Oberfläche von MSCs, was darauf 
schließen lässt, dass Aminosäuretransportfunktionen von Stromazellen für das Überleben 
leukämischer Zellen essentiell sind. Interessanterweise können Leukämiezellen die 
Aminosäure Cystin nur unzureichend importieren, und eine Untergruppe von leukämischen 
Patientenzellen erfordert eine kontinuierliche Zufuhr des Cystin-Metaboliten Cystein für die 
de novo-Synthese von Glutathion, ein wichtiges Antioxidans. Tatsächlich erhält die 
metabolische Transportfunktion von Aminosäuren der Stromazellen den Glutathionspiegel 
der leukämischen Zellen aufrecht. Das hat zur Folge, dass der oxidative Stresspegel 
reduziert wird, und dieser Effekt war spezifisch in genau den leukämischen Patientenzellen 
detektierbar, die eine Abhängigkeit von stromalen BSG/SLC3A2 aufwiesen. Die Zugabe von 
Cystein, nicht aber von Cystin kehrte den Effekt der RNA Interferenz von BSG/SLC3A2 in 
Stromazellen auf das Überleben der leukämischen Zellen um. 
 
Zusammenfassend wird hier die Etablierung einer neuen Plattform für die systematische 
Untersuchung von Interaktionen zwischen primären Leukämiezellen und Stromazellen des 
Knochenmarks beschrieben. Dieser Ansatz wurde durch die Identifizierung von relevanten 
und Leukämie-spezifischen Überlebenssignalen von den Stromazellen validiert. Die hier 
bestätigten spezifischen Interaktionsmuster zeigen neue Möglichkeiten für eine gezielte, 
maßgeschneiderte Krebstherapie auf, sofern geeignete Biomarker entwickelt werden, um 
Patientenkohorten effizient auszuwählen. Die hier beschriebene Plattform kann auch für die 
Analyse von anti-leukämischen Effekten von neuen Substanzen, einzeln und in 
Kombinationen, verwendet werden. Diese Arbeit bereitet die Grundlage für umfassende, 
funktionale genomische, in grossem Rahmen durchführbare Studien und wird die 
Entwicklung von in vivo Modellen vorantreiben. 
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8Introduction 
1. Acute Lymphoblastic Leukemia- diagnosis and treatment 
Acute leukemia is the most common form of cancer in childhood. Although cure rates of 
around 80% can be achieved, 20% of patients with acute lymphoblastic leukemias relapse, 
ranking relapsed leukemia among the top four most common diagnoses in pediatric oncology 
in Switzerland (Swiss cancer registry). Therefore, the current challenges are: the reduction of 
a long and toxic therapy whenever possible, the identification of patients at risk for relapse 
who may profit from therapy intensification and the development of novel treatment 
modalities for patients not responding well to commonly used drugs. 
During hematopoesis, hematopoietic stem cells differentiate in the bone marrow giving rise to 
all lineages constituting the blood (Figure 1). Lesions occurring in the lymphoid lineage at the 
progenitor stages of the differentiation lead to a block of differentiation and aberrant 
proliferation of immature cells. Malignant transformations can occur in early B or T 
lymphocytes, resulting in B or T-acute lymphoblastic leukemia (ALL). After disease onset, the 
massive proliferation of leukemic cells outcompete normal hematopoiesis, explaining the 
relative short time course of disease referred by the word acute. The symptoms present at 
diagnosis are a result of the impaired hematopoiesis in the bone marrow with infiltration of 
extramedullary sites such as liver, spleen and lymph nodes. Most commonly, patients suffer 
from general fatigue, anemia, fever, infections, unusal bruising, pain, enlarged lymph nodes/ 
liver and spleen.  
Fig. 1. Scheme of the hematopoietic tree. Differentiation steps are represented leading from the hematopoietic 
stem cell to the main cells constituting the blood.
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For the diagnosis of ALL, a bone marrow biopsy is required to identify the hematopoietic 
lineage involved in leukemogenesis. Cytogenetics reveal the karyotype of the leukemic 
populations and can identify present translocations, which are important for risk stratification 
of patients and ultimately for the treatment given. The Immunophenotyping performed at 
diagnosis using flow cytometry allows the identification of the lineage and of the maturation 
stage at which the differentiation is blocked. The lineage and maturation stage can be 
identified with a combination of cell-surface markers specific for the differentiation status of 
hematopoietic cells. Leukemic blasts typically have common and aberrant patterns of marker 
expression compared to the cells they originate from, what allows to follow the malignant cell 
population by flow cytometry during the treatment. In parallel, Immunoglobulin (Ig) and T cell 
receptor (TCR) gene rearrangements are assessed. These rearrangements occur during 
normal lymphoid development and represent a fingerprint for each individual cell and its 
progeny. Flow cytometry and PCR assess efficacy of the imposed treatment by identification 
and quantification of residual leukemic cells in the bone marrow during treatment.  
 
Generally, treatment of ALL in Europe is divided in 4 phases [1]. The induction phase aims at 
reducing leukemia burden and if leukemia cells respond well to therapy a drop of leukemic 
blasts in the bone marrow is seen within about 4 to 6 weeks. The intensification phase that 
follows lasts 2 to 4 months with the major aim to maintain remission and to prevent regrowth 
of leukemic cells especially in the central nervous system (CNS), since around 30% of initial 
relapses are found in the CNS [2]. A reinduction phase is alternating intensive therapy with 
therapy pauses and aims at killing the last leukemic cells to avoid future relapses. Finally, the 
subsequent consolidation therapy lasts until 2 years after diagnosis to ensure full remission. 
In cases of poor response to induction therapy or if disease is associated with poor 
prognostic features, hematopoietic stem cell transplantation (HSCT) can be considered. 
However, the use of HSCT depends on availability of donor cells and prospective studies are 
currently being conducted to determine the indication of the different HSCT procedures in 
high-risk or relapse childhood ALL [3-5]. 
 
In the last 30 years, ALL therapy was designed as a multiphase treatment process using a 
combination of cytotoxic drugs that follows risk-directed intensifications. Although treatment 
tailoring allows to achieve cure rates of around 80% [6], the long and intensive treatment 
procedures have high toxic effects, which need to be reduced to a minimum for patients 
responding well to therapy with low risk of relapse. On the other hand, some patients do not 
respond to current treatment modalities and relapses occur frequently in around 20% of the 
cases including all risk groups. The risk-based stratification of patients proved to be the right 
direction to go and needs further understanding and innovation to ensure the amelioration of 
treatment in ALL. Importantly, future research needs to concentrate on understanding why 
some patients relapse and on finding methods to identify them in early phases to adapt 
therapy modalities. 
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2. Prognostic factors in acute lymphoblastic leukemia 
 
A few significant risk factors have been described in childhood ALL, including leukocyte 
count at diagnosis, immunophenotype, age, chromosomal abnormalities and response to 
initial therapy (Table 1) [7, 8]. These risk factors contribute to the stratification of patients and 
are used to optimize their individual treatment. More intensive chemotherapy is given to 
patients with unfavorable factors, whereas favourable factors account for less or modified 
versions of the intensive therapy.  
 
Table 1. Factors used for risk stratification in childhood ALL. 
 
Chrom.= chromosomes. Adapted from [9]. 
 
2.1. Genetic aberrations in ALL  
 
Leukemia is a complex genetic disease. Lesions leading to the malignant transformation of 
progenitor cells include aberrant expression of proto-oncogenes, aneuploidy and 
chromosomal translocations. Cytogenetic analyses identify the ploidy status of leukemic cells 
and can reveal some translocations. Only a few genetic lesions have strong prognostic value 
for risk stratification of the patients (Figure 2). Hyperdiploidy as well as the detection of the 
ETV6-RUNX1 translocation product are seen as favourable prognostic factors [10, 11]. In the 
hyperdiploid patients, around 5% of patients carry the t(1;19) rearrangement, leading to the 
fusion product E2A-PBX1 which is also associated with better prognosis [12]. On the other 
hand, BCR-ABL1 positive leukemias resulting from the translocation t( 9;22), also called 
Philadelphia chromosome, E2A-HLF positive leukemias bearing the translocation t(17;19) 
and leukemias with MLL rearrangements account for unfavourable outcome with higher risk 
of relapse [13, 14].  
 
In the last years, knowledge about mutational diversity has increased due to deep-
sequencing analysis of the genome of individual patients and profiling strategies. Mutations 
were observed in transcription factors regulating lymphoid development such as PAX5, EBF 
and IKZF1 [16], in proteins regulating cell cycle such as CDKN2A and CDKN2B [17], in 
tumor suppressor genes (PTEN and RB1) [16] and in regulators of apoptosis  (BTG1) [16]. A 
candidate gene sequencing approach comparing diagnostic and relapse ALL identified 
alterations in the transcription co-activators CREBBP and NCOR1, as well as in transcription 
factors ERG, SPI1, TCF4 and TCF7L2 [18], that were associated with relapse. 
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Figure 2. Frequency of cytogenetic subtypes of pediatric ALL. Adapted from [15]. The pie chart includes all 
major B- and T-lineage subtypes of ALL, to illustrate the relative frequency of each. The recently described BCR-
ABL1–like subtype and BCR-ABL1 positive ALL are shown in yellow to illustrate the high frequency of childhood 
B-ALL cases with genetic alterations activating tyrosine kinase and cytokine receptor signaling that may be 
amenable to targeted therapy. 
 
Recently, a subgroup referred to as BCR-ABL1-like ALL was identified [16, 19, 20]. These 
leukemias are not bearing the translocation leading to the BCR-ABL1 fusion product but 
show similar gene expression profiles and have an unfavourable outcome. They have 
alterations in the transcription factor IKAROS encoded by the IKZF1 gene. This gene is 
found to be mutated in 76.2% of childhood BCR-ABL1 positive ALL and in 90.9% of adult 
BCR-ABL1 ALL cases [21]. Additional to mutations in IKZF1, mutations in the CRLF2 gene 
were found in 40% of BCR-ABL1-like ALL cases. Normally, CRLF2 dimerizes with IL7RA to 
form a receptor triggering JAK/STAT signalling upon TSLP (thymic stromal-derived 
lymphopoetin) binding. However, mutations in CRLF2 can lead to aberrantly activated kinase 
signalling, as was shown in down syndrome ALL where overexpression of CRLF2 was found 
in association with activating mutations in the receptor itself or with mutations in JAK2 
resulting in a constitutively active JAK/STAT pathway [22]. 
 
The mechanism of cooperation of different lesions and the consequences of mutation 
patterns for each patient are still unclear. In particular, associations of mutational patterns 
and treatment response remain to be determined. Next generation sequencing of primary 
leukemias that are currently underway will help us to understand mutational networks, which 
mutations are driving, cooperating and mutually exclusive. This knowledge will need to be 
completed with a biological understanding of the functional relevance of the mutations, which 
could ultimately lead to the identification of potential drug targets enabling a personalized 
treatment scheme. 
2.2. Risk stratification of patients based on response to treatment  
 
Despite tremendous efforts to identify genetic alterations and attempts to correlate these with 
the outcome of the patients, the best method for risk stratification is the analysis of in vivo 
response to initial chemotherapy. The kinetics showing a reduction in the number of 
malignant cells detected in the bone marrow during the induction phase of treatment allows 
stratifying the patients. The assessment of remaining leukemic cells in the bone marrow by 
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flow cytometry and PCR is called MRD (minimal residual disease) assessment. Several 
studies have independently confirmed the predictive value of this strategy [23-25].  
 
In the AEIOP-BFM-ALL 2000 study, patients are stratified as high risk when more than 1 
leukemic cell per 1000 normal cells was detected (HR; MRD level ≥10-3) at day 78 of 
treatment. HR patients have a 5-year event free survival (EFS) rate of 50.1% compared to 
92.3% in the standard risk group (SR; negative MRD at day 33 with a sensitivity of at least 
10-4) (Figure 3). One additional MRD assessment time point at week 22 allows the 
identification of a subgroup of HR patients with exceedingly high risk for relapse, called very 
high risk patients (VHR). These patients remain resistant to intensive chemotherapy and 
represent a patient group for which better treatment alternatives are needed.  
 
 
 
Figure 3. Event-free survival and cumulative incidence of relapse according to PCR-MRD classification in 
3184 pB-ALL patients. Adapted from [24]. 
The outcome of patients with relapse in ALL has remained static over the past two decades 
[26] requiring the establishment of the best standard treatment strategies and investigating 
innovative therapies. Therefore, a multi-centre study for children with relapsed acute 
lymphoblastic leukaemia was initiated in 2010, called IntReALL 2010. The consortium was 
build between 20 national study groups to recruit enough patients for studying treatment 
strategies within childhood relapsed ALL. The ALL-REZ BFM Study group is taking part, as 
well as the COPRALL Study Group, the NOPHO Study Group, the UKALL Relapse Study 
Group and the AIEOP group. 
Obviously, MRD assessment is helping to stratify patients but the molecular mechanisms of 
persistence remain unclear. Cell intrinsic mechanisms like genetic alterations can render 
cells more resistant but as well cell extrinsic factors can play a role. We focus here on the 
question of the influence of the microenvironment in the support of B-ALL.  
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3. Role of the bone marrow microenvironment in ALL 
 
3.1. Importance of the tumor microenvironment and MSCs 
 
The importance of the microenvironment for a tumor was stated first in 1889 by Stephen 
Paget in his “seed and soil” theory for metastatic dissemination. In the last years, important 
insights into the role of the microenvironment became more and more important, not only for 
metastatic disease but also in primary tumors. In 2011, the tumor microenvironment is stated 
as one the “hallmarks of cancer” stated by Douglas Hanahan and Robert Weinberg [27]. 
Indeed, stromal cells are generally recruited to primary tumor sites to form tumor-associated 
stroma. Some of the stromal stem and progenitor cells seen in different mouse models of 
various carcinomas are recruited from the bone marrow [28, 29]. The bone marrow 
comprises mesenchymal stem cells representing an extremely rare cell type comprising 
0.01% to 0.001% of all mononuclear cells in the bone marrow, compared to 1% for the 
hematopoietic stem cell (HSC) population [30]. Unfortunately, plastic adherent cells isolated 
from the bone marrow are often called mesenchymal stem cells and a controversy arose 
from the extensive use of such cell fractions in the clinical setting without sufficient and clear 
biological characterization of these cells. Only cells with a colony-forming efficiency of 100% 
comprising cells that are uniformly multipotent and self-renewing, as assessed by in vivo 
transplantations, could be called mesenchymal stem cells [31]. Along the same line, it was 
proposed to name this rare stem cell population, skeletal stem cells. A skeletal stem cell 
represents a single cell capable of generating a complete heterotopic bone or bone marrow 
organ (ossicle) in vivo [32]. Bone-marrow derived mesenchymal stem cells should be 
negative for the hematopoietic linage markers CD34 and CD45 [33] and positive for STRO-1, 
CD146, CD105, ALP, CD49a and CD271, among others [31]. Different markers are used for 
the characterization of these stem cells as a consensus, but no marker is known so far to be 
specific uniquely for them.  
Because of the ambiguity related to the name of MSC, I will call mesenchymal stem cells, 
skeletal stem cells and use the acronym MSC for mesenchymal stromal cells. 
The functions of bone-marrow derived mesenchymal cells within tumors are not fully 
understood. In vivo models suggest the migration and engraftment of MSCs at injury sites 
and in neoplasia when inflammation occur [34]. The reported effects of MSC on the 
progression of primary tumors can be pro- as well as anti-tumorigenic and vary widely 
depending on the source of MSCs or the tumor model used [35]. However, MSCs seem to be 
actively recruited to primary tumor sites increasing the complexity of the tumor mass. This 
property is leading to new therapy approaches based on injecting modified MSCs with anti-
tumorigenic properties [36].  
 
3.2. HSCs and their niches 
 
Stem cells need protected and regulated surroundings to maintain their self-renewal 
capacity. The idea of a specific microenvironment for hematopoietic stem cells arose in the 
1970s with an original concept of Ray Schofield saying that functional cell types provide the 
necessary goods to maintain HSC potency throughout life [37]. This specific 
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microenvironment, called niche, is a place where cells “not only reside but are regulated, 
nurtured and protected” [38]. It is thought that HSC are kept quiescent to prevent damage, 
however the kinetics of the HSC cycling in humans are currently not known [39]. At the same 
time, the bone marrow is permissive enough for stress signals to allow activation of HSCs 
upon hematopoietic challenge and replenishment of hematopoietic cells [40]. Up to now, a 
unique and specific HSC niche in the bone marrow could not yet be characterized [41]. This 
could be due to the fact that different functional niches exist for different HSC 
subpopulations, as even highly purified HSC show heterogeneity [41]. Different subtypes of 
bone marrow stromals cells were described to be able to modulate HSC activity, including 
osteoblasts [42], Cxcl12-abundant reticular cells [43] and nestin-positive mesenchymal stem 
cells [44]. 
 
The establishment and maintenance of hematopoiesis during life is intimately connected with 
the circulation of HSC between tissues [45]. A unique trait of HSCs is that they periodically 
leave the bone marrow niche and enter blood circulation. Later, they re-enter the bone 
marrow space, a process which is called homing [46, 47]. Mobilization of HSCs can be 
affected by circadian rhythms [48] and bone remodelling [49]. The circulation of HSCs is 
thought to be important for homeostasis of hematopoietic cells. Hematopoiesis can occur 
directly in distant tissues and the turn-over in the HSC niches guarantees transient periods of 
niche vacancies [46].  
 
The most prominent axis for homing of HSCs is the CXCR4-SDF-1 axis [43, 50]. The 
cytokine SDF-1 is secreted by cells of the niche in the bone marrow generating a gradient. 
HSC cells due to expression of the chemokine receptor CXCR4 are attracted to home back 
to the bone marrow when being in circulation. In the niche itself, adhesion interactions 
involving integrins and VCAM-1 take place and allow retention of HSCs in the niche [51, 52]. 
Signals involving calcium are thought to be important for the correct localisation next to the 
endosteum [53]. Moreover, maintenance and quiescence, as well as self-renewal and 
expansion of HSCs are regulated by cross-talks with cells within the niche. Secreted stem 
cell factor (SCF), thrombopoietin (TPO) as well as angiopoetin1 (ANGTP1) are thought to 
play a role in maintenance and in vivo quiescence of HSCs through interactions with their 
respective receptors KIT, MPL and Tie2 tyrosine kinase (TEK) [54-56]. More recently, 
angiopoetin-like 3 (ANGPTL3) was shown to help controlling HSC quiescence [57].  
 
The Wnt as well as Notch signaling pathway have been implicated in HSC regulation. Due to 
the complexity of those pathways, full understanding of their function in HSC expansion 
remains challenging [41]. For the Wnt pathway, 19 WNT ligands are known to interact with 
secreted and membrane-associated proteins including at least ten transmembrane Frizzled 
(FZD) receptors, two low-density lipoprotein receptor-related proteins (LRP5 and LRP6) and 
an undefined number of extracellular proteins such as Kremlin, Dickkopf (DKK), Wnt-
inhibitory factor (WIF), secreted FZDs (sFRP) and Norrin [58]. Depending on the cell type 
and on the ligand-receptor interactions occuring, the canonical or two different non-canonical 
Wnt pathways can be activated. The canonical pathway results in the activation of beta-
catenin, which translocates to the nucleus and acts as co-activator of transcription factors 
such as TCF and LEF [58]. WNT3a, WNT5a (mostly non-canonical pathway) or activation of 
beta-catenin were shown to influence HSC expansion in vitro and in vivo [59-61]. Moreover, 
the Wnt pathway regulates expression of VCAM-1 in stromal cells [62]. In the Notch pathway, 
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NOTCH1 and NOTCH2 activation influence HSC function over ligand interactions mostly via 
JAG1 [63, 64]. 
 
Interactions of HSC with their niche are summarized in Figure 4. 
 
 
 
Figure 4. Crosstalk between HSCs and their niche. Adapted from [41]. 
 
3.3. Known interactions of B-ALL with the microenvironment 
 
The interactions of B-ALL cells with the microenvironment show similar mechanisms to 
HSCs. The bone marrow acting as a protective microenvironment will have consequences in 
leukemia treatment strategies. Thus the identification of protective signals could lead to the 
development of new anti-leukemic compounds. 
 
Pre-B ALL cells can displace normal HSC upon engraftment in mice [65], indicating that 
leukemia cells are able to hijack the HSC niche. Indeed, B-ALL cells express the CXCR4 
receptor like HSCs, and the SDF-1/CXCR4-axis also plays an important role for homing to 
the bone marrow of ALL cells [66, 67]. SDF-1 can be expressed by epithelial cells of different 
organs including lymph nodes, spleen, liver and brain [68, 69]. Furthermore, the expression 
of CXCR4 on ALL cells correlates with the infiltration in extramedullary sites [70] and the 
activation of the CXCR4 receptor correlates with a poor outcome in B-ALL [71]. Addition of 
SDF-1 enhances survival of B-ALL cultures with stromal cells in vitro [72]. Inhibitors of the 
CXCR4 receptor like AMD3100 were shown to reduce proliferation of B-ALL cells in vitro [73] 
and in vivo [74]. Moreover, administration of AMD3100 sensitized ALL cells to clinically used 
drugs in mice [75]. Although this study stated that leukemic cells are more susceptible to 
AMD3100 than HSC to enter circulation, clinical studies need to assess the effect of those 
treatment strategies on HSC. Until now, clinical trials for AMD3100 are in phase 1/ 2 for 
treatment of AML and show promising results [76].  
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In addition to SDF-1, other cytokines secreted by the microenvironment affect B-ALL cells. 
IGF-1, VEGF, PDGF,  IL-3 and IL-7 [77, 78] [72] were reported to help to sustain B-ALL cells. 
A mechanism that can induce cytokine release in the bone marrow stroma is hypoxia that 
upregulates HIF-1α, an oxygen-regulated protein. In bone marrow from patients with ALL, 
overexpression of HIF-1α was observed [79]. VEGF is a target gene of HIF-1α, which 
stimulates angiogenesis [80, 81]. Increased angiogenesis was observed in ALL [82] and 
expression of VEGFR on leukemic cells upon activation by different VEGF ligands promotes 
proliferation [72]. 
 
Besides the role of soluble factors, contact dependent mechanisms play a role in B-ALL 
support. Similar to HSCs, where intergins ensure retention in the niche via interactions with 
VCAM-1, pre-B-ALL cells express α4β1 integrin (also referred to as very-late-antigen 4, 
VLA4) which via interactions with VCAM1 on niche cells influences the homing and 
engraftment of leukemic cells in mice [83-85]. High expression levels of VLA4 on relapsed 
ALL cells predict adverse outcome and highlights the biological role of direct cell-to-cell 
interactions of leukemic cells with the microenvironment during treatment [86].  
 
As in HSCs, the Wnt and Notch pathway are thought to play a role in survival of B-ALL cells. 
Evidences for the activated Wnt pathway were first found in E2A-PBX1-positive leukemias, 
where the fusion protein activates transcription of WNT16 [87]. However, understanding of 
the possible functions of the Wnt pathway in B-ALL cells seems as difficult as in HSCs. The 
activation of proliferation due to WNT3a [88] stands in contradiction to the inhibition of 
proliferation reported by others [89]. Nevertheless, dysregulation of WNT expression in 
leukemia cells [90] and the overexpression of LEF1, a key mediator in Wnt signaling 
associated with unfavourable outcome [91] confirm an important role for Wnt signaling in 
ALL. Moreover, comparison of diagnostic and relapse cases suggests an involvement of the 
Wnt pathway in relapse [92].  
 
NOTCH1 is a key regulator of differentiation of T and B lineage during lymphopoesis. PAX5 
promotes B cell development by repressing NOTCH1, and pan-hematopoietic PAX5 
expression blocks T lymphopoesis [93]. On the other hand, NOTCH1 activation leads to 
differentiation to the T-lineage and blocks early B cell lymphopoiesis [94]. The Notch pathway 
arose as a major pathway involved in T-ALL with NOTCH1 activating mutations found in over 
50% of T-ALL [95]. The role of NOTCH in B-cell malignancies is still controversial but gains 
importance especially in malignancies involving more mature B cells like chronic 
lymphoblastic leukemia [96]. In B-ALL, induction of Notch pathway via Hes-1 was shown to 
promote apoptosis [97]. However, expression of NOTCH3 and NOTCH4 from stromal cells in 
vitro proved to have pro-survival effects in B-ALL cells [98]. A better understanding of the 
Notch pathway itself is required and will help to clarify the functions of different NOTCH 
receptors and NOTCH ligands. 
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3.4. Protective effects of the microenvironment on B-ALL cells during 
treatment 
 
The microenvironmental signals activate pro-survival signaling in leukemia protecting 
leukemic cells from chemotherapeutic agents. The understanding of these interactions is 
critical to develop novel treatment approaches.  
As briefly introduced, inhibition of CXCR4 on leukemic cells enhanced the cytotoxic and 
antiproliferative effects of vincristine and dexamethasone in vitro [73]. SDF-1 could be shown 
to act on kinase pathways, like the Akt and MAPK pathways, by enhancing phosphorylation 
of ERK1/ 2, p38MAPK and Akt [78]. The PI3K/AKT/mTOR pathway is an essential 
intracellular pathway regulating growth and survival of cells and is often found to be mutated 
in cancer [99]. Clinical trials using mTOR inhibitors like sirolimus or temsirolimus are currently 
investigated in pediatric ALL [100]. The MAPK pathway regulates gene expression and cell 
survival among others [101]. The MAPK pathway involves many kinases regrouped in 3 main 
branches namely the ERK pathway, p38MAPK and JNK kinases [101]. p38MAPK inhibitors 
were stated to reduce ALL cells survival in vitro [72]. The JAK/STAT pathway playing an 
important role in ALL, is connected to the AKT and to the MAPK pathways [100], leading to a 
complex intertwined network of intracellular kinase signalling in ALL. 
Moreover, stromal VCAM-1 enhanced resistance of ALL cells to cytarabine and etoposide in 
vitro [102], probably through activation of integrin linked kinases in leukemia cells [103, 104]. 
The induction of anti-apoptotic proteins upon interaction with the microenvironment may 
contribute to achieve resistant phenotypes upon treatment. VEGF was shown to inhibit 
induced apoptosis in B leukemic cells through phosphorylation of BCL-2, a member of the 
anti-apoptotic family [105]. Moreover, stromal cells were shown to reduce Caspase 3 activity 
of B-ALL cells leading to a reduction in apoptosis after treatment with cytarabine and 
etoposide in vitro [106]. An overview over the cellular pathways currently targeted as 
potential therapeutic approaches in pediatric ALL (B and T-ALL) is depicted in Figure 5. 
Probably CXCR4 and VEGF only represent a small number of the cytokines affecting B-ALL 
support. More contact dependent mechanisms than VCAM-1 need to exist and the protective 
effect of the microenvironment can not be limited to the upregulation of the anti-apoptotic 
pathway. The knowledge of microenvironmental protection of B-ALL cells is still very limited 
and requests further investigation. 
 
The complexity of aberrant signalling pathways is further increased by aberrant metabolism 
occurring in cancer cells. Indeed, an important hallmark of cancer cells is their differential 
metabolic activity compared to normal cells [107]. The preferential nonoxidative use of 
glucose via glycolysis in cancer cells was stated by Otto Warburg in 1956 and could be 
confirmed in AML cells [108]. The understanding of metabolic reprogramming of cancer cells 
gained importance in the last years. The metabolic alterations found in cancer cells get linked 
to oncogenic signaling and are dependent on the tissue type in which oncogenesis occurs 
[109].  KRAS influences the activity of the oxidative pentose phosphate pathway in a 
pancreatic cancer model [110]. The oncogene MYC influences glutaminolysis and renders 
cancer cells addicted to glutamine [111]. Thus, MYC overexpressing cells, like some 
neuroblastoma subtypes, are sensitive to glutamine deprivation [112]. Oncogenic mutations 
were found to occur in metabolic enzymes and the idea of oncometabolites arose. IDH1 and 
IDH2 mutations found in glioblastoma and AML, lead to increased levels of 2-
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hydroxyglutarate, which modifies the epigenetic regulation of the cells by DNA methylation 
[113, 114].  In chronic lymphoblastic leukemia, the deficiency of cystine import was overcome 
by continuous supply of cysteine by stromal cells. [115]. Cysteine is needed for the synthesis 
of the anti-oxidant glutathione, which is critical to control oxidative stress in leukemic cells. 
Again, for ALL cells there was only one important study reporting microenvironmental help to 
maintain their elevated metabolic rate. ALL cells have low asparagine synthetase (ASNS) 
expression levels with low asparagine biosynthesis and are therefore exquisitely sensitive to 
asparagine depletion when treated with asparaginase. However, ALL cells are protected in 
the presence of bone marrow stromal cells, which have high ASNS expression levels and 
compensate asparagine biosynthesis even upon depletion with asparaginase [116].  
 
 
 
Figure 5. Cellular pathways under investigation as potential therapeutic targets in pediatric ALL. Adapted 
from [100]. With the exception of Aurora Kinase, which is required for mitotic spindle assembly, all other kinases 
included here are purple and activate the PI3K-Akt and/or Ras-MAPK prosurvival pathways. Cluster of 
differentiation (CD) surface marker proteins are pink. Proteins of the apoptotic pathway are yellow. Molecules 
involved in protein degradation are green. Transcription factors are blue. Compounds in development as targeted 
therapeutics are described in black boxes.  
 
Most studies investigating microenvironmental interactions were conducted for HSCs. Some 
pathways were found to play a role in the interactions B-ALL cells undergo with their 
microenvironment and of these only a few were linked to protective effects against 
chemotherapy. Furthermore, the maintenance of elevated metabolic rates in cancer cells 
gained importance in the last years but mostly did not investigate B-ALL. Further studies are 
required to characterize the microenvironmental interactions specifically in B-ALL. 
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4. Models of leukemia and leukemic microenvironment 
 
4.1. Maintenance of B-ALL cells in vitro 
 
The first B-ALL cell line, REH, was established in 1974 from leukemic cells of a girl with 
relapsed ALL [117]. Many lines are derived from resistant disease or relapse cases mostly 
harbouring t(1;19) or t(9;22) translocations [118]. In our laboratory, only the establishment of 
cell lines from cases positive for the t(17;19) translocation proved to be successful. In 
general, the establishment of childhood B-ALL cell lines is difficult with success rates of 
about 10% The acquisition of stromal independence is difficult to achieve and seems to be 
associated with different translocations. Moreover, additional cytogenetic aberrations can 
occur in vitro [117] and the maintenance of clonal heterogeneity in cell lines is not clear. 
Thus, cell lines do not represent well the diversity that is characteristic for ALL. 
 
Primary ALL cells rapidly die in suspension cultures in vitro and the maintenance of primary 
leukemic cells in vitro only by addition of cytokines was only possible in few cases. Some 
reports show that B-ALL cells can be supported by addition of IL-3, IL-7 and SCF in vitro 
[119]. However, other groups, including ours, could not reproduce these data [120]. The only 
efficient way of supporting B-ALL cells in vitro is to co-culture the leukemic cells with stromal 
cells, a methodology used since 30 years [121]. Stromal cells provide the required multitude 
of survival cues like adhesion molecules and secreted cytokines. Moreover, human leukemic 
cells are supported on murine-derived stroma, indicating that important microenvironmental 
interactions are maintained from mouse to human [122]. Only in stromal co-cultures, addition 
of cytokines (IL-3, IL-7, SDF-1, VEGFs or PDGF) can further enhance short-term survival of 
leukemic cells  [72, 78]. 
 
Stromal cells can be isolated from different tissues like the placenta [123], the aorta wall, the 
thymus, the spleen or the bone marrow [124]. Bone marrow derived MSC form healthy 
donors can be expanded on a regular basis. However, experimental variability can result 
form differential culture and expansion conditions and differential genetic backgrounds. 
Ideally, MSC should be derived from each patient to study matched leukemia and 
microenvironment interactions. However, the availability of primary MSC is restricted and the 
establishment of MSC cell lines of each patient with validation of MSC characteristics is 
challenging. Therefore, several different cell lines derived from primary bone marrow cells 
are routinely used for experimental set-ups in vitro. The OP-9 cell line was derived from the 
calvaria of a newborn mouse [125] and was shown to be useful in ensuring mouse 
embryonic stem cells to differentiate into HSCs [126]. The MS-5 cell line was established 
from adherent cells in long term bone marrow cultures of mice after irradiation and proved to 
support growth of HSC for longer than 2 months in vitro [127]. The HS-5 cell line is derived 
from human bone marrow and was immortalized by transduction with the human papilloma 
virus E6/E7 genes [128]. HS-5 cells could support the proliferation of hematopoietic 
progenitor cells when co-cultured in serum-deprived media with no exogenous factors and 
expressed high levels of VCAM1 [128]. The MSC cell line is derived from human bone 
marrow and was immortalized by enforced expression of telomerase [129]. This cell line has 
the same growth properties than primary MSCs. They show the same doubling time, they are 
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not forming tumors in immunodeficient mice and have the potential to differentate to 
osteoblasts and chondrocytes [129]. Moreover, they are supporting normal and leukemic 
hematopoiesis [129]. Co-cultures of MSCs with primary B-ALL cells proved to sustain viability 
of leukemic cells in a majority of cases [130, 131]. Long-term support could result in an 
amplification of cells in some cases, but extensive short-term proliferation of B-ALL cells in 
the co-culture system was not reported [130, 131]. Moreover, the survival analyses of 
leukemia cells co-cultured with MSC cells could predict treatment outcome in patients [132]. 
We preferentially worked with the cell lines of human bone marrow origin. There, we 
preferentially used the MSC cell line showing a normal karyotype. The HS-5 cell line 
displayed numerical and structural abnormalities (data not shown). 
 
4.2. Models of B-ALL cells in vivo 
 
Animal models are required for studying cancer in vivo. Especially for treatment modalities 
the in vivo proof of efficacy is indispensable. For B-ALL, transplantation of HSC transduced 
with leukemia specific fusion genes like BCR-ABL1 or MLL fusion genes are used and can 
be useful to look at additional genetic lesions arising in vivo [133, 134]. However, these 
models using fusion genes address very specific subgroups and do not recapitulate the 
complexity of B-ALL. Xenotransplantions of primary patient material in immunodeficient NSG 
mice proved to recapitulate genetic complexity and phenotype of the patients [135, 136]. 
After transplantation, the proportion of human cells is assessed in the peripheral blood of 
mice to follow engraftment and expansion of leukemic cells (see Figure 6). Intravenous or 
infemoral injections of human cells into mice lead to development of human leukemias after 
few weeks with a dissemination pattern similar to the ones observed in humans. Clones 
present after xenotransplantation could in the majority of the cases be backtracked to clones 
present at diagnosis [136]. Most importantly, the numbers of cells recovered range from few 
millions in the bone marrow up to a billion of cells in the spleen. Thus, transplantation in mice 
leads to an impressive amplification of leukemic material. It constitutes in theory a renewable 
source of primary B-ALL cells for systemic functional experiments of cases where extensive 
clinical and diagnostic data are available. 
 
It is of note that leukemia progression and evolution of ALL subclones analyzed in xenograft 
models are depending on the model used [137]. Although mircroenvironmental cues from 
mouse and humans are conserved to some extend and cross-species experiments in vitro 
and in vivo are possible, the study of microenvironmental interactions of leukemic cells with 
their corresponding human niche in vivo remains challenging. 
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Figure 6. Establishment of leukemia xenograft mouse model. Adapted from [138]. Cells derived from fresh or 
biobanked human bone marrow aspirates (1) are transplanted into immunodeficient mouse recipient (2) and 
leukemia development and progression is monitored in peripheral blood by means of flow cytometry. Leukemia 
developed in mice morphologically, phenotypically and genetically resembles original human disease (3). 
Leukemia xenograft model serves as renewable source of material for further experiments (4).  
 
4.3. Models of the microenvironment in vivo 
 
Knockout mice are one possible tool to study relevant mechanisms in vivo by comparing wild 
type and knockout mice of the same strains for specific questions. Engineering of knockout 
mice can be long and ineffective but innovative techniques in the last years promise fast and 
cost-effective results [139]. Especially in studies that investigate the microenvironment of 
HSCs, knockout mice gave some unexpected results when looking at complex pathways 
such as the Wnt or the Notch pathway [140-142]. Ultimately, knockout mice can only provide 
satisfactory answers asking simple questions in known settings where no redundant proteins 
can rescue the investigated phenotype. Furthermore, translation into humans always needs 
to be further proven. 
 
The reconstitution of a humanized niche in immunodeficient animals and further manipulation 
of this reconstituted humanized niche would constitute a model to study niche functions in 
vivo. Currently, the repopulation of human MSCs injected in mice is not efficient due to low-
survival rates and poor long-term engraftment rates [143]. Pre-conditioning of MSC with 
SDF-1 or hypoxia could enhance survival rates after transplantation [144, 145]. The up-
regulation of CXCR4 on MSCs enhanced the engraftment rates in the bone marrow of NSG 
mice [56] and ectopic expression of integrin α4 could increase retention of MSC in the bone 
of mice [146]. But further improvements are required to model the microenvironment in vivo 
with injected human MSCs.  
 
One possibility in creating human niches in vivo is the use of so called humanized mice, 
which carry functioning human genes, cells, tissues and/or organs. The formation of ectopic, 
extramedullary bone in mice is one of the approaches in modelling human bone marrow-like 
microenvironment in an in vivo setting [147, 148]. MSCs on polyurethane scaffold could 
mimic a human bone marrow stromal network with presence of adipocytes, osteoblasts and 
blood vessels and enabled the growth and maintenance of inoculated human AML cells 
[148]. Another model illustrated in Figure 7, uses endothelial colony-forming cells (ECFCs), 
which are blood- or vasculature-derived endothelial progenitor cells (EPCs), mixed with 
MSCs and Matrigel [147]. 8 weeks after injection in NSG mice, well-vascularized bone like 
structures developed. HSC and an AML cell line proved to be able to engraft in this 
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extramedullary bone structures. This model further provides the basis to alter the 
extramedullary micronvironment by genetic modifications of the MSCs used. Indeed down-
regulation of HIF-1α in the MSC compartment lead to 50% decrease of engrafted leukemic 
cells in the ectopic bone environment [147]. 
 
 
 
 
Figure 7. Schema of extramedullary bone/marrow generation. Adapted from [147]. MSCs and ECFCs were 
isolated from heparinized human BM or peripheral blood through an initial adhesion step and subsequently 
allowed to proliferate in specific media. Cells mixed with Matrigel were subcutaneously injected into the flanks of 
NSG mice, and these developed into bone-like tissues with high osteoblastic activity in 8 weeks. 
 
 
The further development of humanized mice will lead to in vivo models resembling more the 
human settings. Although the NSG mouse model allows robust lymphopoesis upon 
engraftment of HSC, few human myeloid cells and no human erythrocytes or platelets are 
generated [149]. This is partially explained by the fact that recipient mice have compromised 
lymphoid compartments but normal myelopoesis with generation of erythrocytes, platelets 
and other myeloid cells. On the other hand, mouse cytokines do not support myelopoesis the 
same way as human cytokines do. The expression of human IL3, SCF and GM-CSF in NSG 
mice proved to enhance engraftment efficiency in AML models [150] and expression of 
human IL-3 and GM-CSF supports human macrophage development [151]. Furthermore, 
human TPO increases the levels of human engraftment in the bone marrow of mice, 
improving the multilineage differentiation of hematopoietic cells, with an increased ratio of 
myelomonocytic versus lymphoid lineage cells [152]. Moreover, the engineering of more 
similar human immunity in mice will be of importance when looking at cancer as the immune 
system is involved in cancer progression [149]. 
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5. In vitro screening systems  
 
Personalized therapy based on “the characteristics of leukemic cells and hosts” identified by 
innovative screenings systems are required to further improve treatment outcome as stated 
in the latest review of Ching-Hon Pui [153]. In vitro screenings are getting more 
comprehensive, and whole genome siRNA studies [154] or compound studies involving few 
hundred thousands of compounds [155, 156] are reality. The ultimate consequence of high 
throughput screenings is the down-scaling of individual conditions. This down-scaling implies 
analyses of few cells in 384 well-plate [157] or 1536 well-plate format [156]. Even smaller 
scales are possible with the spotting of siRNAs and cells on chips giving rise to cell 
microarrays with 30 to 500 cells per spot [158-160]. 
 
5.1. Co-culture systems for screens within a microenvironmental context 
 
In leukemia, in vitro studies need to be conducted assessing leukemia cell responses within 
their microenvironmental context. Therefore, 2-layer systems have been established to 
screen for drugs killing leukemia cell lines using a stromal layer and leukemic cells plated on 
top [161]. Due to the amount of cells needed to conduct high-throughput screens, usually first 
cell lines are used and hits are verified in a second step in primary cells [162, 163]. Recently, 
a high-throughput compounds screening methodology was reported using primary mouse 
AML cells [164]. In the case of AML, a smaller scale kinome screening study with primary 
cells was reported identifying known, activating mutations in JAK2 and K-RAS, as well as  
a previously undescribed, somatic, activating mutation in the thrombopoietin receptor [165]. 
Screening studies using primary cells were performed for other cancer types like ovarian 
carcinoma testing 3 patient samples for 3000 compounds [166]. The development of 
screening studies goes more and more in the direction of 3D models of different tumor 
microenvironments [167, 168] and ultimately in vivo screenings can be performed [169]. 
Momentarily, large scale in vivo screenings seem to be restricted to RNA interference 
systems. Gene sets using shRNA pools are downregulated in leukemic cells, which are then 
transplanted into mice and populations with a growth advantages are identified by 
sequencing. However, compound screenings in large scale in vivo settings are technically 
not feasible. 
 
5.2. Advantages of image-based screenings 
 
For the establishment of an in vitro high-throughput screening technology, the assay 
development depends on the platform and read-out used to perform the screen. Automated 
imaging using automated microscopes and automated analysis of images made it possible to 
conduct high throughput screenings based on visual phenotypes of individual cells [170].   
The key steps of the development of an image-based screening are depicted in Figure 8.  
 
The requirements for new in vitro screening technologies are high. The methods developed 
should be fast, cost-effective, user friendly, reliable and applicable to different experimental 
questions [160, 170]. The assay we developed has the aim to assess reliably viable cell 
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numbers of both cell types in a co-culture set-up in a 384 well-plate format. In the end, the 
addition of one solution to the plate was enough to perform automated microscopy and upon 
image analysis to identify living ALL cells and MSCs. 
 
 
Figure 8. Key steps for establishing an image-based high-throughput screening method. Adapted from 
[170]. 
 
The assay I developed requires the use of an automated microscope and the analysis of the 
co-cultures images acquired. The image analysis protocol involves a machine learning step, 
where teaching of the software by the human eye and criteria of scientists can correct and 
implement complex cellular phenotypes in the computational process. These protocols can 
be downloaded for free and are thus made accessible to any laboratory and convey to 
requirements made by the high-throughput screening community [171].  
 
Image-based analysis is not only used to determine cell proliferation or death but can find 
many applications: identification of cell death induced [154], intracellular localisation of 
proteins, morphology of organelles, kinetics of divisions [172], morphology of cells [154] or 
more complex phenotypes like angiogenesis [173] and whole organisms like the zebrafish  
[174] can be looked at. Ultimately, the image based approach can provide further insights in 
the interactions taking place between leukemic and stromal cells beyond the question of 
viability. Further development of the method has a great potential in answering relevant 
biological questions, also in regard to the protection of leukemic cells by the 
microenvironment. 
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Subject of Investigation 
 
 
Microenvironmental interactions of B-ALL cells remain poorly investigated. Functional 
investigations of the microenvironment in human ALL are limited by the difficulty to conduct 
large scale in vitro studies. The amount of primary cells needed to conduct such studies 
became available by xenotransplantation of human leukemia cells in immunodeficient mice 
providing a powerful tool to model disease and amplify cells.  
 
The major aims of my PhD Thesis were to: 
 
• Establish a methodology using the co-culture system of primary leukemic cells with 
stromal cells to conduct large scale in vitro studies (manuscript 1)  
 
• Investigate functional interactions of the microenvironment and childhood precursor 
B-ALL cells using RNA interference of stromal genes to identify new mechanisms of 
support (manuscript 2).  
 
 
Manuscript 1: Multimodal high-content screening platform to study primary leukemia cells in 
co-culture with bone marrow stroma (first author). 
 
In this manuscript, a detailed protocol is provided for the developed screening platform on 
how to conduct RNA interference or compound screening studies. Especially the set-up and 
different optimization steps of the platform are described. 
 
 
Manuscript 2: Selective metabolic dependence of acute lymphoblastic leukemia on oxidative 
stress protection by bone marrow stroma (first author). 
 
In this manuscript, I aimed for the identification of protective cues from MSCs that promote 
survival of primary B-ALL cells using RNA interference. The downregulation of Basigin (BSG) 
proved to decrease ALL cell survival in a large subset of B-ALL cases. Among BSG 
interacting proteins, I identified a member of the solute carrier family 3 (SLC3A2) that 
displayed the same phenotypic effect. SLC3A2 proteins play an important role in importing 
and exporting amino acids, including cystine. A subset of patient samples proved to be 
sensitive to cystine depletion and required continuous supply of cysteine by stromal cells. 
Cysteine enabled B-ALL cells to synthesize glutathione and to cope with their elevated ROS 
levels. The role of stromal cells in this important pro-survival mechanism was not previously 
acknowledged for primary B-ALL cells. 
 
This manuscript includes the main part of the biological findings of my work and thus will be 
the essential part in the discussion section. 
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ABSTRACT 
We describe here a simple and robust protocol to conduct high-content screens with primary 
leukemic cells in co-culture with bone marrow stromal cells in a 384 well-plate format. The 
addition of a single fluorescence dye to the co-cultures is sufficient to identify living acute 
lymphoblastic leukemia (ALL) cells and mesenchymal stromal cells (MSCs) using automated 
microscopy and a specifically developed image analysis pipeline. This open source platform 
enables identification of both cell compartments at the same time. It can be used for RNA 
interference studies, or to generate activity profiles of small molecules as single compounds 
and in combinations, and can be adapted to other cell types. The image acquisition and 
analysis pipeline takes 5 to 9 hours per plate and enables a rapid evaluation of leukemia cell 
viability after any perturbation.  
INTRODUCTION 
Innovative in vitro high-content screening methods are demanded for rapid and efficient 
translation of new anti-leukemic strategies into preclinical models [1]. The bone marrow 
microenvironment represents a candidate site for leukemic cells to escape chemotherapy, by 
promoting resistance of leukemic cells to chemotherapeutic agents due to numerous 
interactions affecting intracellular signalling [2-4]. Compounds to which leukemia cell lines 
were sensitive proved to be less effective in presence of stromal cells [5, 6]. The 
microenvironment may counteract treatment strategies and in vitro studies need to be 
conducted within a microenvironmental context to avoid unnecessary failures in further 
validation steps. Moreover, primary leukemia cells only survive in vitro using a co-culture 
system with mesenchymal stromal cells indicating that stromal cells provide survival cues for 
primary ALL cells [7, 8]. We therefore sought to establish a co-culture system for high-
content screens with primary leukemia cells co-cultured on mesenchymal stromal cells. Due 
to the amount of cells needed to conduct such high-throughput screens, cell lines rather than 
primary cells were used so far [6], and hits were verified in a second step with primary cells 
or in vivo [9-11]. Based on the possibility to expand primary ALL cells in vivo in xenograft 
models, sufficient primary leukemic cells for high-throughput functional studies can be 
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generated. Xenotransplanted leukemia cells recapitulated the original disease reliably, 
indicating their usefulness for disease modeling [12-14]. We used the protocol described 
here to assess supportive signals that originate from mesenchymal stromal cells and sustain 
leukemia cell survival using RNA interference of candidate genes at stromal level (Boutter et 
al, 2013). Moreover, the assay is used in our laboratory to generate drug response profiles in 
precursor B-ALL and T-ALL and can be adjusted to other cell types than acute lymphoblastic 
leukemia cells (see Fig. 9 for an overview).  
Fig.9. Overview of the high-content screening platform to study primary leukemia cells in co-culture with 
bone marrow stroma. The steps required only for RNA interference studies are depicted in blue. The steps 
required specifically for compound screens are shown in green. During image analysis, images are segmented 
(spots detected are marked by an inner and an outer ring). 52 intensity and texture features are assigned for the 
inner and outer ring of each spot. The Advanced Cell Classifier (ACC) is assigning the spots that represent living 
ALL cells (based on the extracted features and on teaching) and analyzes the whole plate. The number of viable 
ALL cells for each well on a 384 well-plate can be plotted as a heatmap.
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The generation of drug response profile could be implemented in a preclinical setting with the 
aim to identify potential candidate compounds or combinations for the development of 
alternative treatment regimens that subsequently can be tested in experimental models in 
vivo. Our platform is versatile, and provides the possibility for combination of different dyes to 
investigate several cellular phenotypes. 
 
The image-based approach we use to assess live and dead cells allows separation of both 
cellular compartments. Alternative methods such as spectrophotometry based protocols 
cannot differentiate between the two cellular compartments, and flow cytometry based 
approaches are not amenable for high throughput procedures. In viability analyses using 
MTT measurements that rely on detection of mitochondrial activity, the signals in MSCs were 
between 10 to 100 fold higher than in leukemic cells, rendering detection of differences in 
leukemia cells difficult. One particular advantage of this protocol is the fact that any effects 
on both cellular compartments can be verified in a second step by re-analysis of the original 
images. Especially in conditions where a high decrease in leukemia cell viability is observed, 
effects on stromal cells have to be considered.  
 
The method presented here allows performing staining and microscopy in a nested manner. 
While for the first plate images are acquired, a second plate can already be processed for 
microscopy. The maximal amount of plates run for a day depends on the speed of the 
automated microscope and the staining protocol used. With our live cell imaging protocol we 
reach a maximum of 12 plates per day for compound screens with an automated microscope 
(image acquisition is one hour per plate). The image analysis pipeline and software are freely 
available under www.highcontentanalysis.org. We focus in this description on the reliable 
detection of living ALL cells. The main challenges for the analysis were to distinguish living 
ALL cells from dead cells and from sub-cellular compartments of the MSCs (eg. MSC 
nucleoli have similar size and intensity than the ALL cells). On the other hand, the method 
should be robust against different imaging conditions and pitfalls, such as vignetting effect, 
noise, or changes of illumination. To meet these demands, a two step approach was 
established. First, we used an ‘a trous’ wavelet transform-based spot detection algorithm to 
reliably detect ALL cells [15]. This method amplifies spots of a given size and suppresses 
non-corresponding spots (Fig. 10). The algorithm was implemented in the MatLab software 
and was built into the CellProfiler framework [16].  
 
 
Fig.10. The CellProfiler software assesses the spots on an image. An ‘a trous’ wavelet transform-based 
algorithm was implemented in the CellProfiler software to improve the spot recognition. After spot detection, the ‘a 
trous’ wavelet transform-based algorithm transforms the images by amplifying spotsof a given size and 
suppresses non-corresponding ones. After this transformation, images are segmented and intensity and texture 
features are assigned for each detected spot. 
 
For each detected spot on an image, over 50 intensity and texture-based features are 
extracted. The intensity features of detected spots consist for example of minimum, 
maximum, mean or standard deviation of the underlying pixels. The texture-based features 
are used to describe the homogeneity of staining pattern seen for each detected spot. None 
of the extracted features was per se able to reliably separate living ALL cells from 
misdetections. Therefore in a second step, we decided to use a multi-parametric approach 
automatically combining features. We used the Advanced Cell Classifier program [17], which 
is a supervised machine learning tool for high-content analysis (Fig. 11A). The Random 
forest classification method proved to be the most powerful classification method to detect 
ALL cells out of six methods tested [18] (see Fig.11B). The ACC relies mostly on intensity-
based features to assign living ALL cells (see Fig.11C). 
 
The assay we describe is performed with a live cell staining procedure and remained stable 
for up to 3 hours after staining (see Figure 12). We could not identify a dye that allowed 
maintenance of a reliable live and dead cell staining pattern after fixation of the co-cultures. 
The use of a live cell dye system restricts the amount of plates that can be screened for one 
given time point of analysis considering the speed of the automated microscope used. As a 
consequence, analyses like whole genome RNA interference screens with few hundreds of 
plates or compound screens assessing few hundred thousand of compounds are not feasible 
using live cell imaging, and will need development of live cell dyes amenable for fixation. 
The protocol we present is suited for smaller scale screens such as whole kinome siRNA 
screens or screens using customized libraries (RNAi or small molecules) to study functionally 
primary leukemic cells in co-cultures. 
 
Fig.11. The Advanced Cell Classifier software identifies living ALL cells in the co-cultures with high 
accuracy. (A) Teaching the ACC manually the difference between living ALL cells (blue arrow) and MSCs or 
dead ALL cells (red arrow) enables the algorithm to assign all spots on each image that fulfil the criteria of living 
ALL cells and MSCs (blue boxes versus red boxes). The ACC shows a high correlation between the teaching and 
the assignement (classification) of cell phenotypes. Low false detection rates are important. (B) The correct 
classification depends on the classification method used. We assessed six different classification metrics (KNN=K 
nearest neighbor; LogitBoost=logistic regression with boosting; MLP=multilayer perceptron; Naïve Bayes; 
Random forest; SVM=support vector machine). Random forest classification reaches the highest accuracy across 
validations using 5-fold cross validation and the best values for the Area Under the Curve (AUC of ROC curve, 
which is an analysis tool to select optimal models and to discard suboptimal ones) and thus reaches the lowest 
average rank. 13 independent datasets from different days and patient samples in co-culture were used for these 
measurements. (C) The 52 extracted features used for spot recognition are shown ranked by their performance. 
Intensity features of the inner and outer ring are more important than texture-based features as reflected in their  
relative importance rank. IRI = inner ring intensity; ORI = outer ring intensity; IRT= inner ring texture;
ORT = outer ring texture
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Experimental design 
 
Testing of the co-culture  
Among different stromal cell lines tested, only cell lines retaining growth inhibition by cell-to-
cell contact were appropriate for this microscopic read-out. For RNA interference of genes at 
stromal level, peptide based transfection reagents proved to subsequently affect ALL cell 
viability much less than lipid-based transfection reagents. We further assessed different 
ratios of cells for the co-cultures and found the ratio of ALL cells to MScs of 10:1 to result in 
stable survival of ALL cells, and down-scaled the conditions to the 384 well-plate format with 
reproducible results using 2500 MSCs with 25 000 ALL cells. The adaption to the 384 well-
plate format represents an important step in down-scaling the co-culture system as 75% of 
cells are spared compared to 96 well-plates, and the throughput can be considerably 
increased. The reduction to a 1536 well-plate format could even provide further reduction of 
cell numbers required, with an additional increase in the speed of the analysis, however care 
needs to be taken with respect to the stability of the system. The density of leukemic cells in 
vitro proved to be crucial due to paracrine factors [19] and the variability between wells could 
become critical and may require automated pipetting using robotics.  
 
Optimize the staining procedure 
We took advantage of the CyQUANT® Direct Cell Proliferation Assay and changed the 
protocol for adaptation to microscopy based read-outs. Compound A of this assay stains the 
nuclei of all cells, both dead and living, and compound B quenches the fluorescence of 
compound A in dead cells and in the medium resulting in low background levels. The staining 
procedure can be adapted to different cell types used. Generally, for more cells more 
compound A is needed. To ensure good distinction between living and dead cells the ratio of 
compound A to compound B for a given cell number is critical. Equilibrium between 
compound A and B, which lasts for a few hours, must be reached before imaging. After a few 
hours, diffusion of compound A from living cells occurs and compound B looses its 
quenching functions leading to an overlap of dead and living cell staining intensity (see 
Fig.12A). The time until equilibrium is reached and its duration can be assessed by 
performing time course experiments with repetitive analyses (see Fig.12B). Depending on 
how the automated microscope proceeds through the plate (left to right for example), control 
wells over the whole plate should be included. Only in equilibrium conditions, the staining 
remains stable over time, which results in control wells with the same viable cell numbers 
independently of their positions on the plate. Moreover, we advise to validate the microscopy 
method by performing experiments in parallel with an alternative method (e.g. flow 
cytometry). We further optimized the staining procedure by replacing the 2 step addition of 
staining solutions described for RNA interference studies by the usage of a single addition 
step used in the protocol described for compound screens 
Fig.12. The staining of the co-cultures is stable for 3 consecutive hours. (A) Clear intensity differences are 
seen for living and dead ALL cells one hour after incubation with the staining solution. After 5 hours of incubation, 
the differences of intensities gets smaller and no clear distinction is possible between living and dead ALL cells. 
(B) Two plates with co-cultures of ALL and MSCs treated with Dexamethasone or Daunorubicine were assessed 
reliably until 3 hours post-staining. 
Proceed with quality control experiments 
In the 384 well-plates, positive and negative controls should be present in adequate numbers 
and preferentially following random patterns. We also included one control row covering the 
whole length of the plate. For RNA interference, we used negative control siRNAs and 
siRNAs affecting the MSCs resulting in loss of leukemia cell viability. The siRNA library can 
be diluted in daughter plates where positive and negative controls are present. The volume 
of siRNA solution in the daughter plates can be adapted to the number of plates and 
replicates to be performed per screening round. For drug screens, DMSO control wells and 
drugs that proved to kill leukemia cells in most of the cases tested are used. We used 5 
concentrations 1nM, 10nM, 100nM, 1µM and 10µM, to calculate accurate IC50 values. The 
compound library with a concentration of 10mM is used to do serial dilution to achieve 
desired concentrations in daughter plates. Pipetting schemes and dilutions can be adapted 
freely to the desired conditions. Importantly, we did not see any changes in the standard 
deviations of cell numbers if the seeding of the cells and/or the staining procedure was 
performed manually or with a pipetting robot (data not shown). We recommend the use of 
pipetting robots to respect complex pipetting schemes, if required. 
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MATERIALS 
 
REAGENTS 
• MSC cell line (Applied Biological Materials Inc., cat. no. T0523) 
• ALL cells: primary human cells isolated from the spleen after transplantation in NSG 
mice  
• CyQUANT® Direct Cell Proliferation Assay with compound A and B (Life 
Technologies, cat. no. C35011 or C35012)  
• RPMI-1640 medium (e.g., Life technologies, cat. no. 21875091)  
• Penicillin-Streptomycin, liquid (e.g., Life technologies, cat. no.15140148) 
• Heat inactivated FBS (e.g., Life technologies, cat. no.10082147)  
• Hydrocortisone (Sigma-Aldrich, cat. no. H0888) 
• Trypsin/EDTA (e.g., Life technologies, cat. no. 25200-056) 
• Compound libraries (e.g., Tocris Bioscience, cat. no. 2884) 
• DMSO (Sigma-Aldrich, cat. no. D8418) 
• AIM-V medium (Life technologies, cat. no.12055091)  
• siRNA oligonucleotide libraries (e.g., Thermo Scientific) 
• INTERFERin transfection reagent (Polyplus transfection, cat. no. 409-10) 
• Nulcease free water (Qiagen, cat. no. 129114) 
• Positive control siRNAs (Qiagen, cat. no 1027281) 
• Negative control siRNAs (Qiagen, cat. no 1027299 and Thermo Scientific cat. no. D- 
001810-01-05) 
 
 
EQUIPMENT 
• 384 well-plates for microscopy, black with clear bottom (Thermo Scientific, cat. no. 
4332) 
• 384 deep well-plates for diltutions (Greiner bio-one, cat. no. 781280) 
• Aluminium sealing Films (Axygen, cat. no. PCR-AS-200) 
• Multichannel pipette with 12 channels (e.g., Eppendorf, cat. no. 4861000139) 
• Reservoirs (Nalge Nunc International, cat. no.370905) 
• Automated liquid handling robot (e.g., Eppendorf, cat. no. 5070 000.719) with 
recommended tips  
• Automated fluorescence microscope with environmental control and 10x objective 
(e.g., Molecular Devices, ImageXpress Micro microscope) 
• Computer with MatLab software 
• Hard drives/ server for storage of images 
 
 
REAGENT SETUP 
 
MSC Medium RPMI-1640 is supplemented with 0.5% (v/v) penicillin-streptomycin, 1µM 
hydrocortisone and 10% (v/v) heat inactivated FBS 
Growth medium RPMI-1640 is supplemented with 0.5% (v/v) penicillin-streptomycin and 10% 
(v/v) heat inactivated FBS 
Medium for transfection RPMI-1640 is supplemented with 0.5% (v/v) penicillin-streptomycin  
 
EQUIPMENT SETUP 
 
For experiments with RNA interference libraries or compound libraries, the use of an 
automated liquid handling robot is recommended. Complex pipetting schemes can be pre-
programmed and used for each experiment. 
 
 
 
PROCEDURE 
 
MSC seeding 
1. Prepare MSC for RNA interference studies (option A) or for compound screenings (option 
B). 
A) RNA interference studies 
(i) Dilute the siRNA library with nuclease free water and prepare daughter plates 
using the 384 deep well-plates including positive and negative siRNA controls in a 
randomized pattern with a final concentration of 240 nM. Store the mother and 
daughter plates sealed at -80°C. 
(ii) Trypsinize MSC cells and resuspend the pellet in growth medium having 50’000 
cells/ ml.  
(iii) Pipette 10µl of siRNA from the daughter plates (240 nM) into the 384 well-plates 
for microscopy. 
(iv) Prepare the transfection reagent mix with per well 0.5 µl of INTERFERin and 19.5 
µl medium for transfection and add 20 µl of transfection reagent mix to each well 
containing siRNAs.  
(v) Vortex gently the plate and incubate for 10 minutes at room temperature.  
CRITICAL STEP The same batch of the transfection reagent should be used for 
the whole experiment. Therefore, we recommend testing different batch numbers 
of the transfection reagent and then using only one batch for all screening 
procedures. 
(vi) Add 50 µl of MSC cells in growth medium (2500 cells) to each well (manual or 
robot pipetting) and place the plates in the incubator for 24 hours. 
B) Compound screening 
(i) Trypsinize MSC cells and resuspend the pellet in growth medium having 50’000 
cells/ml.  
(ii) Add 50 µl of MSC cells in growth medium (2500 cells) to 384 well-plates for 
microscopy (manual or robot pipetting) and place the plates in the incubator for 24 
hours. 
CRITICAL STEP MSC cells are slowly proliferating and should always have a density 
between 40 and 80% with regular passaging to avoid dedifferentiation. Low-number 
passage should be used. Hydrocortisone is toxic for leukemia cells and should not be 
added when plating MSCs for co-cultures. 
 
ALL seeding 
2. Prepare ALL cells for RNA interference studies (option A) or for compound screenings 
(option B). 
A) RNA interference studies 
(i) Thaw the frozen ALL cell aliquots using growth medium and spin down the cells. 
Resuspend the pellet in AIM-V medium with a final dilution of 500’000 cells/ ml.  
(ii) Remove medium from transfected MSC cells and add 50 µl of ALL cells 
(25’000cells) in AIM-V medium (manual or robot pipetting). Place the plates in the 
incubator for 6 days. 
B) Compound screening 
(i) Dilute the compound library with DMSO to a final concentration of 10mM and 
prepare daughter plates using the 384 deep well-plates. Store the mother and 
daughter plates sealed at -80°C. 
(ii) Thaw the frozen ALL cell aliquots using the medium and spin down the cells. 
Resuspend the pellet in growth medium so that 25’000ALL cells are in 57,5µl.  
(iii) Remove medium from MSC cells and add 57.5 µl of ALL cells in growth medium 
to each well (manual or robot pipetting). Place the plates in the incubator for 24 
hours. 
(iv) After 24 hours, add 5ul of the compound library daughterplates to the co-culture 
plates using a pipetting roboter. Follow the deployed pipetting scheme to obtain 
on the same plate the desired concentrations for each drug. 
 Staining of co-cultures  
3. Stain co-cultures for RNA interference studies (option A) or for compound screenings 
(option B). 
A) RNA interference studies 
(i) Prepare Cyquant staining solution in AIM-V medium to add 25µl per well reaching 
a final dilution of component A of 1:375 and of component B of 1:75. 
(iii) Add 25µl of staining solution to each co-culture well (manual pipetting) and place 
the plates in the incubator for 45 minutes.  
(iv) Remove staining solution carefully. 
(v) Add 30µl of AIM-V medium with compound B diluted 1:100 and incubate the plate 
for 1 hour at 37°C, 5%CO 2. 
B) Compound screening 
(i) Prepare Cyquant staining solution in growth medium to add 20µl per well reaching 
a final dilution of component A of 1:1240 and of component B of 1:80. 
(ii) Add 20µl of staining solution to each co-culture well (manual pipetting) and place 
the plates in the incubator for 1 hour. 
TROUBLESHOOTING 
 
Automated microscopy 
4. Put the plates into the automated microscope with powered environmental control (37°C, 
5%CO2) 
5. Load your settings (plate type, objective type, fluorescence settings of the green channel 
and focus settings) and check that the plate is in the focus and the illumination time is 
adequate. CRITICAL STEP Used plates need to be configured in the automated 
microscope as the focus settings and plate sizes are highly dependent on the plate types 
used. Illumination time needs to be adapted to be in the optimal range of pixel intensity. 
Wells with the highest cell number (usually negative control wells) should be unsaturated 
allowing a maximal range of intensity changes in images for the analysis. 
6. Start the imaging. PAUSE POINT 
 
Image analysis  
7. Image segmentation and feature extraction 
(i) Go to the folder where the images from the automated microscope are stored and 
create 3 new folders named ‘anal1’, ‘anal2’ and ‘anal3’. Layout of the folders 
should be a Project folder containing a Plate folder containing the 3 anal folders 
with the tif files from the automated microscope. 
(ii) Rename the images if necessary using the Plate folder name, followed by the well 
and the number of the image (if more than one image per well was taken).  
(iii) Start MatLab and open CellProfiler. 
(iv) Load the analysis pipeline “ALL_10x_pipe” into the CellProfiler 
(v) Load the images from the automated microscope by inserting the address of the 
Plate folder into the CellProfiler windows “Default Image Folder” and “Default 
Output Folder” 
(vi) Click on Analyze images. PAUSE POINT 
 
8. Machine learning 
(i) Open Matlab and load the Advanced Cell Classifier (ACC) script. 
(ii) Open a new project and select the Project folder containing all files. 
(iii) Select 384 well-plate in “plate type” 
(iv) Start selecting living ALL cells and mark them as positive examples.  
(v) Select dead ALL cells, debris and nucleoli of MSC cells and mark them as 
negative examples.  
(vi) Click on “train classifier” and choose the classifier SimpleLogistic.weka and click 
on Train. 
(vii) Go to your positive and negative controls and check that only living ALL cells are 
recognized. CRITICAL STEP Recognition should be easy and few positive and 
negative examples (n=20) are sufficient for the ACC to accurately recognize the 
cells.  
(viii) If the training gives satisfactory results, click on “Predict selected plates”. The 
analysis will be stored in the folder anal2 as excel file named 
*name_cumul_1_v_1_2* and contain the numbers of living ALL cells per well. 
PAUSE POINT 
TROUBLESHOOTING.  
 
9. Quality control 
Once the staining is performed, the plate can be imaged for consecutive 3 hours (see 
Fig.12). The standard deviations for the same conditions achieve maximally 20% (see Fig. 
13). Viability decrease of ALL cells in biological replicates was reproducible with low standard 
deviations. For technical replicates, the variability can increase especially in compound 
screens, where the IC50 depends on a curve fitting process taking place on a logarithmic 
scale (see Fig.13). Therefore we recommend using 2 parameters to assess the effect of a 
compound on ALL cell viability, i.e. IC50 and area under the curve (AUC). 
 
TIMING 
Step 1: 1 to 4 hours for transfection studies (optionally automated) 
Step 2: 2 to 10 hours for compound addition to plates (automatically) 
Step 3: 1 to 2 hours 
Step 4 to 6: up to an hour, depending on the speed of the microscope and numbers of 
images taken 
Step 7: 2 to 4 hours 
Step 8: 1 to 2 hours 
Step 9: typically done before screening procedure during optimization steps, per screen 
around 15 min are needed.  
 
TROUBLESHOOTING 
Step 3.  
• If the cell numbers for the same conditions on a plate are not equal (e.g., show a 
gradient from left to right) the staining equilibrium was not reached. 
• If the staining is too faint, more compound A is needed. 
• If no clear distinction can be made between living and dead cells based on the 
staining intensity (positive and negative control wells have the same staining pattern), 
not enough compound B was used. 
Step 8.  
• As different patient samples can have different cell staining phenotypes, it is 
recommended to use one primary cell type per teaching in the ACC step.  
• If living cells were detected in the positive control wells but a clear distinction 
between positive and negative control wells is possible, re-perform the machine 
learning process in step 8, using more examples for living and dead cells. 
• During teaching, it is best to use clear examples of living ALL cells and examples of 
recognized spots which are clearly not living ALL cells. The Advanced Cell Classifier 
software will implement the information of these clear examples and extract features 
living cells should have. Even in difficult images, the ACC will be able to recognize 
the correct classification. One should not try to classify the cells where no clear 
phenotype is recognizable, as this would weaken the decision-making process of the 
algorithm. 
 
Fig.13. High reproducibility of replicates is achieved for RNA interference and compound screen studies. 
(A) Results of treatment of MSC with positive control, siRNA for BSG or negative controls are shown with SEM for 
interplate and interexperiment replicates for one patient sample. (B) Negative control and 2 IC50 values for two 
different drugs are shown for intraplate and interplate replicates. (C) The dose response curves used to assess 
SEM of biological replicates in (B) are shown.  
 
  
ANTICIPATED RESULTS 
The co-cultures display patient specific characteristics requiring a machine learning step. 
With this approach a reliable assessment of primary living ALL cells from different cases in 
co-cultures is possible. Examples of images from different patient samples in co-culture with 
clear ALL cell viability decreases achieved by RNA interference or with small molecules 
compared to the negative controls, are shown in Fig.5 A. Images with suboptimal staining 
conditions are shown in Fig. 5 B. The conditions where not enough compound B is used are 
most difficult to recognize, as dead cells will appear stained. However, all wells in the plate 
will look the same and show the same cell number after analysis. Moreover, dead cells don’t 
show a co-culture pattern seen in Fig. 5A, but are typically equally distributed over the well. 
Moreover, examples of images with normal and affected MSC layer are shown in Fig.5B. 
Even in difficult images, the ACC is usually able to recognize the requested phenotypes, and 
gives correct ratios for the investigated effects. However, we recommend optimizing staining 
and experimental conditions to ensure a good reproducibility of obtained results. 
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J.B., A.R. and V.F. performed experiments and analyzed data; A.V. helped in setting up the 
platform; P.H. established the image analysis pipeline; B.B. and J.-P.B. designed research 
and all authors wrote the manuscript.  
 
 
Fig.14. Microscopy images of co-cultures of different patient samples. (A) In the negative control images, 
patient-specific patterns in the co-cultures are seen, e.g. some ALL cells cluster more than others. Less viable 
ALL cells are seen after RNA interference of BSG in stroma, the positive control and for 2 drugs used at ≈IC50. 
(B) Images with suboptimal staining conditions are shown. In conditions with insufficient compound A, ALL cells 
are not brightly stained. In conditions with insufficient compound B, dead ALL cells appear stained. (C) Effects 
on MSCs are detected reliably. A comparison with a normal phenotype of the MSC layer (left) and with affected 
MSC layer (right) is given. 
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ABSTRACT 
 
Interactions with the bone marrow microenvironment are essential for leukemia cell survival. 
We developed an image-based RNA interference platform to identify protective cues from 
bone marrow derived mesenchymal stromal cells (MSCs) that promote survival of primary 
acute lymphoblastic leukemia (ALL) cells. Using a candidate gene approach, we detected 
specific and distinct contributions of stromal genes to survival of individual ALL samples. The 
strongest effects were observed after downregulation of the vascular endothelial growth 
factor C (VEGFC) or of Basigin (BSG, alias CD147). Dependence from stromal VEGFC 
predicted sensitivity to VEGF receptor kinase inhibitors. BSG expression was required to 
provide metabolic support to a subset of ALL via SLC3A2, which forms heterodimeric amino 
acid transporters (HAT) on MSC. Cystine import by stromal HATs provides the limiting 
substrate to generate cysteine for ALL cells. This metabolic interaction maintains glutathione 
levels and reduces oxidative stress specifically in ALL cases that were dependent on stromal 
BSG/SLC3A2. Thus, functional evaluation of intercellular interactions between leukemia cells 
and their niche with such a platform will provide a new layer of personalized information for 
the development of rationale treatment combinations. 
 
 
 
  
 
 
 
INTRODUCTION 
 
Leukemia cells subvert normal hematopoietic stem cell niches and can infiltrate sanctuary 
sites such as the central nervous system to escape therapy [65]. Microenvironmental 
interactions are important for leukemia cell survival, and maintenance of primary leukemic 
cells in vitro is achieved by co-culture with stromal cells [121, 122]. The intercellular crosstalk 
between leukemia cells and their microenvironment is strongly influencing their cellular states 
and their responsiveness to chemotherapy [102, 161]. The identification of leukemia-specific 
patterns of intercellular dependence will possibly provide new options to refine treatment.  
Mesenchymal stromal cells (MSC) that are derived from human bone marrows support 
leukemia survival in cocultures. [129, 131] and reconstitute functional hematopoietic niches 
in vivo [147, 184]. Explanted MSC include multipotent skeletal progenitors that can form 
heterotopic bone in transplantation models. Evidence from mouse models indicate that the 
hematopoiesis-supporting niche is derived from mesenchymal stem cells [41, 44]. These 
cells, which can regenerate bone tissue with osteoblasts and stroma in vivo, were localized 
to the perivascular space [31]. The pathways and molecular interaction that determine the 
hematopoietic stem and progenitor cell niche are explored using different experimental 
models [185]. Only a few mechanisms have been described that support leukemia 
propagating cells in precursor B acute lymphoblastic leukemia (BCP-ALL). Factors that 
contribute to the localisation of leukemia cells in the niche such as the chemokine receptor 
CXCR4 [67, 186] or the α4β1integrin, VLA-4, have been implicated [85, 86]. Growth factors 
such as SDF-1 and VEGF were critical to maintain certain BCP-ALL samples in stromal co-
cultures [72]. Given the metabolic deregulation with increased dependence on glycolysis 
observed in myeloid leukemia cells [108], dependence on metabolic support from stroma 
could be essential for leukemia survival.  
Here we have developed an image-based platform for functional genomic interrogation of the 
intercellular crosstalk between leukemia and bone marrow derived MSCs. Our recently 
established xenograft model of ALL [136, 187] enabled systematic functional evaluation of 
patient derived primary leukemia samples. Using a candidate gene approach, we identified 
reproducible patient specific dependence patterns on stromal gene expression, involving 
different pathways. The most detrimental effect on leukemia survival was achieved by down-
regulation of Basigin (CD147, BSG) on stroma, which we show to be critical for the function 
of an amino acid transporter including the subunit SLC3A2. A subset of ALL samples was 
critically dependent on metabolic support from stroma cells to protect them from oxidative 
stress, suggesting important underlying differences between individual leukemias with 
respect to metabolic deregulation. As recently shown in a model of chronic lymphocytic 
leukemia, we could confirm that the protective mechanism involved production of cysteine to 
maintain gluthathione levels in leukemia cells, resulting in protection from oxidative stress 
[115]. 
 
 
 
  
 
 
 
RESULTS 
 
Bone marrow derived mesenchymal stromal cells provide different pro-survival cues 
to support B-cell precursor ALL  
 
Bone marrow derived, immortalized MSCs have been established to support leukemia cell 
survival in a model of the leukemia microenvironment [129]. With the aim to use this system 
for the functional investigation of critical intercellular interactions between leukemia and 
stromal cells, we determined the kinetics of 24 primary BCP ALL samples on human MSC in 
the 384 well-plate format (Fig. 15 and suppl. Table 1). These samples included cases from 
different prognostic groups based on clinical criteria [24] (Suppl. Table 1). In single cell 
suspension cultures, the viability dramatically decreased within one week (Figure 15A and B 
and data not shown). In contrast, 21 out of 24 ALL samples were maintained alive on stroma 
in serum-free culture conditions (Fig. 15B). As reported previously [131], such cultures could 
be maintained over weeks by serial replating on MSCs (not shown). Out of the three cases 
that showed proliferation, a sample with a translocation t(17;19) could be established as a 
cell line under serum-containing conditions (VHR-23). Only 3 samples could not be 
maintained in MSC co-cultures, suggesting important differences in the dependence from 
microenvironmental factors among different ALL samples. Neither supplementation of the 
culture medium with FCS nor a change of the medium formulation influenced the results 
significantly (data not shown). We next used the transwell system to physically separate the 
two compartments, in order to understand to which extent direct cell-to-cell contact was 
required for survival support for 7 selected cases (Fig. 15C). While a majority of the samples 
clearly depended on contact-mediated support, 2 cases that carried the translocations 
t(17;19) and t(1;19), respectively, were maintained by soluble factors only. Collectively, these 
results suggest important underlying differences among ALL samples with respect to the 
dependence from the microenvironment. Given the marked difference in survival observed 
within one week of culture with or without MSC support, we hypothesized that this model 
would reflect important interactions and could serve as a platform for functional 
investigations.  
 
 
 
  
 
 
 
 
Fig. 15. Bone marrow derived mesenchymal stromal cells (MSC) provide different pro-survival cues to 
support B-cell precursor ALL. (A) Comparison of viability of ALL cells in suspension or in co-culture with MSCs 
for 6 days was assessed by flow cytometry using CD45 and 7-AAD staining. (B) 24 BCP-ALL cases were tested 
for their survival on MSCs after 6 days of co-culture. Viable cell numbers at days 6 were compared to the viable 
cell numbers of primary ALL cells assessed at day 1. SR: standard risk group. HR: high risk group. VHR: very 
high risk group. MNR: morphological non responder, relapse cases. (C) Comparison of ALL cell viability in co-
culture with MSCs (MSC+ALL), separated via a Transwell (MSC/ALL) or in suspension culture alone (ALL) after 3 
days. SR-02 is carrying a t(1;19) and VHR-01 a t(17;19) translocation. Viability was assessed by FACS and 
performed at least in duplicates and normalized to the viable cell numbers of primary ALL cells assessed at day 1. 
 
 
Automated live cell imaging facilitates large-scale cell viability analysis of leukemia 
co-cultures on MSCs 
 
To analyse adherent co-cultures of two cell types without disrupting their interactions, we 
developed a microscopy-based screening platform in a 384 well format that is suitable for 
assays at large scale (Fig. 16). Optimal cell culture conditions were met with 25’000 leukemia 
cells per well in a 10:1 ratio on MSCs, which is relevant given the limited availability of 
primary patient material. Use of a live cell permeable fluorescent dye resulted in the best 
contrast between living ALL cells and MSCs, enabling the discrimination of ALL and MSC 
nuclear structures using the same fluorescence channel by microscopy (Fig. 16A). Image 
acquisition was set to cover more than half of the well’s surface area. For image analysis, an 
‘a trous’ wavelet transform-based spot detection algorithm was implemented using the 
  
 
 
CellProfiler software to identify ALL cells [179, 180]. To further avoid misdetections, ALL cells 
were classified using a machine-learning program called Advanced Cell Classifier (ACC) 
[181]. A good correlation of the cell viability data that was obtained by automated microscopy 
and 7-AAD staining analyzed by flow cytometry of the same experiments was reproducibly 
achieved, an example is provided in Fig. 15B. This constitutes the basis of a platform for 
small molecule and RNA interference screening.  
 
 
 
Fig. 16. Automated live cell imaging facilitates large-scale cell viability analysis of leukemia co-cultures 
on MSCs. (A) Workflow of the image-based assessment of ALL cell viability using the live cell dye Cyquant in the 
co-cultures in the 384 well-plate format. After automated microscopy which generates 9 images per well covering 
more than 50% and image segmentation using CellProfiler, the number of living ALL cells per well was assessed 
with the machine learning program Advanced Cell Classifier (ACC). (B) Correlation of living ALL cells assessed 
by ACC and by flow cytometry. In total, 5 experiments were run in parallel for both methods. To get the full range 
of possible ALL cell viabilities, conditions with negative control siRNAs and positive control siRNAs (killing the 
MSCs) as well as incubation with chemotherapeutic agents (dexamethasone, daunorubicin and vincristine) in 
different concentrations and seeding different numbers of cells were used. (C) Western blot showing the 
downregulation of Integrin beta 1 over a time period of 6 days. (D) Work flow for RNA interference screening: 24h 
after reverse transfection of MSC cells, ALL cells were added for 6 days in co-culture before live staining and 
automated microscopy was performed. 
 
 
 
  
 
 
Intercellular interactions are case-specific 
 
To identify critical determinants of stromal support in our model, we established a workflow 
for RNA interference in MSC cells (Fig. 16B, C). We then customized a small RNAi library for 
110 selected candidate genes based functional annotation that were indicative of a role in 
cell adhesion, signalling, interactions with the extracellular matrix or a role in a hematopoietic 
stem cell niche function, and evidence from own gene expression profiling data and cell 
surface proteome data in MSC that these genes were expressed and that putative interaction 
partners were present on ALL cells (Suppl. Table 2). Because we expected to detect distinct 
patterns for different patients, we proceeded in two steps. We first performed a screen in 
triplicates with three cases (VHR-01, VHR-03 and VHR-04) and detected reproducible 
patterns in each case (suppl. Table 3). Interestingly, we did not detect any candidate gene in 
MSCs that supported all three cases but selected 20 genes with strong activity based on 
RNA interference in two out of the three cases and extended our analysis on BCP-ALL 
samples from 10 different patients (Fig. 17A). Interference with these genes did not affect 
MSC viability or morphology (data not shown). Only 3 out of the 20 selected genes did not 
reach significant effects on leukemia cell viability decrease (suppl. table 3). The contribution 
of the individual candidate stromal genes varied for each leukemia sample that we tested. 
Some of the hits included genes that have been reported to contribute to the normal 
hematopoietic niche function, such as components of the WNT/beta-catenin pathway and the 
NOTCH pathway. For others, direct or indirect evidence for interactions with ALL cells have 
been reported. VCAM1 was reported to mediate stroma-ALL interactions through the binding 
of VLA-4 [102, 188]. The cytokine TSLP stimulates a pathway that is also frequently mutated 
in BCP-ALL [22, 189], suggesting that stromal TSLP could be relevant in this context. 
VEGFA was shown to be expressed by stromal cells and to support leukemia cell viability in 
stromal co-cultures [72, 190]. We found VEGFA and VEGFC to be expressed in MSCs and 
tested both cytokines. Validation experiments confirmed that down-regulation of VEGFC 
affected survival strongly in two of 10 ALL samples (Fig. 17B). As a proof of concept, the 
sensitivity of samples to VEGFC RNA interference correlated with the sensitivity to two 
different small molecule inhibitors of the VEGF receptor (Fig. 17C), suggesting that this 
approach may identify targets for tailored therapeutic intervention.  
 
 
  
 
 
 
 
 
Fig. 17. Identification of patient specific signals from MSCs supporting for ALL cell viability by RNA 
Interference. (A) The siRNA screen for downregulation of 20 genes on stromal level was performed with 10 ALL 
patient samples in duplicates. Depicted is the mean survival for each patient compared to the mean survival of 
each patient assessed in the negative controls wells. The red bar indicates the median effect on normalized ALL 
cell viability for the 10 patient samples tested for one gene. (B) The down-regulation of VEGFC on MSC level 
differentially affects the 10 ALL patient samples. The results of the siRNA screen presented in panel A are 
depicted as histograms showing the mean ± SEM. (C) VEGFR inhibitors (Axitinib and Cediranib, shown for 1µM) 
were used to block VEGFR signalling in the co-culture with the 3 patient samples indicated. Both inhibitors 
decreased cell survival in the samples that were sensitive to VEGFC downregulation in MSCs, but not in those 
that did not respond to the downregulation, n=2. (D) ALL cell viability assessed by flow cytometry for 18 patient 
samples tested in co-culture after down-regulation of BSG on MSC level. The co-cultures with negative siRNA 
controls were used to normalize the numbers of living ALL cells. The histograms show the mean ± SEM, n=1 
(samples w/o error bars) to n ≥ 3. 
  
 
 
The multifunctional stromal cell membrane protein Basigin (BSG/CD147) contributes 
most prominently to ALL support  
 
The strongest loss in ALL viability was observed after down-regulation of Basigin 
(CD147/BSG) in MSCs. This membrane glycoprotein has been directly implicated in cancer 
biology. BSG was shown to modulate matrix metalloproteinase activity [191] and S100A9 
[192] on the surface of cancer cells, which is important for cell invasion and migration. BSG 
also interacts with different membrane transporters, including monocarboxylate transporters 
to support glycolysis in cancer cells [193]. Here we identified a critical function of BSG from 
the tumor microenvironment. We next evaluated the importance of stromal BSG expression 
for 18 leukemia samples that we had identified to be dependent on stromal support  
(Fig. 17D). Interestingly, most of the ALL samples that we tested depended on stromal BSG 
expression, one third of them very strongly, but three samples remained completely 
unaffected. Dependence or independence on BSG contact was not associated with known 
clinical characteristics, such as resistance to therapy (Fig. 17D and suppl. Table 1).  
Taken together, our approach identified several stromal genes to interact functionally with 
leukemia cells in a specific way, because these cues were required for a subset of leukemia 
samples, each of which would show different patterns of dependence. The prominent 
identification of BSG suggested its possible role in stabilisation of critical intercellular 
interactions such solute carriers to support the metabolism of ALL cells. 
 
The stromal amino acid transporter subunit SLC3A2 is required for the support of BSG 
dependent leukemia.  
 
To identify the mechanisms of BSG-mediated prosurvival activity in our model, we evaluated 
the contribution of 16 proteins that were previously described to interact with BSG to the 
support of ALL by MSC. The gene that clustered most closely with BSG with respect to 
survival support in our assay was SLC3A2 (Fig. 18A). SLC3A2 is a member of the solute 
carrier family and corresponds to the large subunit of a heterodimeric membrane amino acid 
transporter (HAT), suggesting the importance of amino acid trafficking between the two 
cellular compartments for the pro-survival function of MSCs, at least for a subset of leukemia. 
Interestingly, this approach clustered the 10 patients into 2 groups, based on overall higher 
activity of these genes in one cluster, including metalloproteinases and integrins (Fig. 18A). 
In addition, we also evaluated the effect of monocarboxylate transporters, including MCT1 
and MCT4, which are stabilized by BSG to exert important metabolic functions for cancer 
cells by modulating glucose metabolism [193]. Interference with MCT1 and MCT4 expression 
did not correlate with the pattern seen for BSG and did not result in a significant decrease of 
viability in any investigated case, nor did it influence lactate levels in the medium (data not 
shown). Validation studies using flow cytometry confirmed that downregulation of SLC3A2 
reliably mimicked the effect of BSG downregulation (Fig. 18B). Both interventions did not 
result in changes in MSC morphology or MSC proliferation rates (data not shown). RNA 
Interference of both BSG and SCL3A2 simultaneously did not increase the effect, suggesting 
that the function of the HAT is limiting in this context (Fig. 18B). Given the reported evidence 
for an interaction between BSG and SCL3A2 [194], our data suggest that BSG is required for 
a critical function of the HAT on stromal cells which is specifically required for the survival of 
a subset of leukemias in this model of the niche. 
  
 
 
 
 
Fig. 18. Functional interaction of BSG and SLC3A2 identified by RNA interference. (A) Heatmap displaying 
ALL cell viability for 10 patient samples tested after the downregulation of 16 genes that are related to BSG 
assessed by microscopy. (B) Validation by flow cytometry of the effect of SLC3A2 downregulation, which 
recapitulates the BSG sensitivity pattern of samples. Histograms show the mean ± SEM of ALL cell viabilities 
compared to the respective negative controls, n= at least 4 
 
 
BSG/SLC3A2 activity protects BSG-dependent ALL from oxidative stress  
 
The importance of HAT activity for stromal support of ALL suggested the possibility of a 
metabolic interaction. Given the recent report that chronic lymphoblastic leukemia (CLL) cells 
depend on stromal cysteine production to maintain glutathione (GSH) synthesis for protection 
from oxidative stress, we next evaluated the contribution of BSG/SLC3A2 to the control of 
ROS levels in ALL cells. RNA interference of BSG or SLC3A2 resulted in a decrease of GSH 
in MSC, which did not affect their viability (data not shown). Comparing three leukemia 
samples that were strongly dependent on stromal BSG/SLC3A2 expression to three samples 
that remained unaffected by the knockdown of these genes, we detected a clear correlation 
of the reduction of ALL survival with an increase of ROS and a decrease of GSH in BSG 
dependent ALL samples upon interference with BSG/SLC3A2 expression (Fig. 19A-C). BSG-
dependent ALL thus appears to be dependent on stromal HAT function to maintain GSH 
levels and regulate ROS. Consistent with this hypothesis, we also found BSG-dependent 
ALL cells to be more sensitive to oxidative stress using hydrogen peroxide, an effect that was 
potentiated by interference with BSG/SLC3A2 in stromal cells (Fig. 19D). Our data support 
the notion that a relevant subset of ALL cases depends on stromal HAT function to cope with 
oxidative stress.
Fig. 19. BSG/SLC3A2 activity protects BSG-dependent ALL from oxidative stress. (A) Viability of patient 
samples sensitive (grey, n=3) and non-sensitive (black, n=3) to downregulation of BSG or SLC3A2 at MSC level 
measured by flow cytometry (*** P<0.001). The order of the samples is respected in every graph as depicted in 
the legend. (B) GSH levels measured with GSH-Glow were reduced in the 3 sensitive samples when BSG or 
SLC3A2 were downregulated at MSC level compared to non-sensitive samples (** P<0.01). (C) ROS levels 
measured by flow cytometry analyses of DCF-DA levels in the cells were increased in the 3 sensitive samples 
compared to non-sensitive samples (*** P<0.001). Histograms in A, B and C show the mean ± SEM of ALL cell 
viabilities compared to the respective negative controls, n= at least 3. (D) Sensitivity to H2O2 was assessed by 
microscopy in the 3 sensitive samples compared to the 3 non-sensitive samples and was increased in the 3 
sensitive samples when BSG of SLC3A2 were downregulated, n=2. 
Interference with stromal BSG/SLC3A2 can be rescued by cysteine and antioxidants  
Because RNA interference of stromal SCL3A2 in the presence of sufficient amounts of 
cystine resulted in loss of ALL cell viability, it is possible that this perturbation interferes with 
stromal metabolism of cystine to cysteine to affect the GSH steady state in our model. To 
address this question, we performed rescue experiments in cystine depleted cell culture 
medium. As predicted, cystine depletion per se was detrimental to BSG/SLC3A dependent 
leukemia, suggesting that interference with HAT function decreases the supply of cystine for 
metabolism in MSC. We could detect a clear dose dependent effect of decreasing cystine 
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concentration in the medium with a marked effect on leukemia samples that are dependent 
on BSG/SLC3A (Fig. 20A). Addition of cysteine, but not cystine, fully rescued the effect of 
stromal BSG or SLC3A deficiency, indicating that stromal cell metabolism from cystine to 
cysteine is critical (Fig 20B). This effect correlated with a decrease in ROS levels after 
cysteine addition. The fact that cystine alone did not rescue ALL cells also confirms that 
leukemia cells have a limited capacity of uptake and metabolism of cystine and depend on 
the availability of cysteine. Importantly we could replicate these experiments using a second 
independent human stromal cell line, HS-5 (Fig. 21). Finally, supplementation of the medium 
with GSH, addition of the antioxidant N-acteylcysteine (NAC), or z-Vad, a pan-caspase 
inhibitor (Fig. 20C and data not shown) rescued the effect of BSG/SCL3A2 downregulation 
as well, confirming that GSH is a critical component of the mechanism involved and that 
control of oxidative stress is required to prevent apoptosis. Based on these experiments we 
propose that, in analogy to a recent report for CLL [115], cysteine production from the 
microenvironment is required for GSH synthesis and control of ROS in a relevant subset of 
ALL cases to prevent apoptosis. 
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Fig. 20. Downregulation of stromal BSG/SLC3A2 is rescued by cysteine and antioxidants. (A) Viability 
assessed by 7-AAD stainings and flow cytometry after 6 days of co-culture with MSCs of 3 sensitive (grey) and 3 
non-sensitive (black) samples in RPMI medium was decreased in cystine depleted medium in sensitive samples 
compared to non-sensitive samples. Supplementation of cysteine rescued cell viability in a dose dependent 
manner. The order of the samples is respected in every graph as depicted in the legend. (B) Viability assessed by 
FACS after 6 days for 3 sensitive (grey) and 3 non-sensitive (black) samples after downregulation of BSG or 
SLC3A2 at MSC level was restored by addition of cysteine (100µM) but not cysteine (100µM) in AIMV medium.  
(B’) Under the same conditions, ROS levels measured by flow cytometry analysis of DCF-DA after 3 days of co-
culture were decreased to control level upon addition of cysteine but not cysteine. (C) Viability of ALL cells 
assessed by flow cytometry after downregulation of BSG or SLC3A2 (upper panel) and ROS levels (lower panel) 
were rescued upon addition of NAC (5mM) or GSH (5mM). Histograms show the mean ± SEM of ALL cell 
viabilities or the MFI ± SEM of DCF-DA analyses normalized to the respective negative controls. Experiments 
assessing the viability of ALL with rescue of cystine or cysteine were performed in quadruplicates. The other 
experiments were performed in duplicates. 
  
 
 
 
 
Fig. 21. Downregulation of stromal BSG/SLC3A2 is rescued by cysteine in HS-5 cells. Viability was 
assessed by FACS after 6 days for 3 sensitive (grey) and 3 non-sensitive (black) patients when BSG is down-
regulated at HS-5 level with addition of cystine (100µM) or cysteine (100µM) to AIM-V medium. In the same 
conditions, ROS levels were measured by FACS assessing MFI of DCF-DA after 3 days of co-culture. The order 
of the patients is respected in every graph as depicted in the legend. Histograms show the mean ± SEM of ALL 
cell viabilities or the MFI ± SEM of DCF-DA normalized to the respective negative controls, n=2. 
 
 
DISCUSSION 
 
Interactions of leukemia cells with their microenvironment have an influence on critical 
cellular programs in cancer cells, with implications for resistance to currently available 
treatment [195]. To facilitate large-scale functional investigation in a model of the leukemia 
niche, we developed this imaging based platform using primary cells from patient samples on 
bone marrow mesenchymal stromal cells. The development of representative collections of 
ALL xenograft samples greatly improves our capability for systematic functional studies [135, 
136, 178, 196]. The methodology reported here can be adapted for selective perturbation of 
one of the two cellular compartments by RNA interference and for systematic profiling with 
bioactive molecules or therapeutic agents. We established an open source modular image 
analysis pipeline with an efficient machine learning based algorithm to discriminate living 
cells in co-cultures upon any of these manipulations. We show that relevant patient specific 
information can be obtained using this platform by profiling functional interactions between 
MSC and leukemia cells. To a significant proportion, ALL were metabolically vulnerable to 
cysteine supply by MSC in order to maintain their redox state. This stromal function is 
mediated by the multifunctional cell surface protein CD147/Basigin and depends on 
heterodimeric aminocid transporters (HAT) including the SLC3A2 subunit. 
  
 
 
 
Most of the BCP-ALL cases that we evaluated depended on MSC for survival in vitro, even in 
presence of exogenous serum factors. These observations are consistent with the difficulty 
to establish permanent cell lines with primary ALL cells and constituted the rationale to 
exploit this system for functional genetic investigations. We recognize that this in vitro model 
of the leukemia microenvironment has limitations. New approaches will be required to model 
our findings in the context of a humanized bone marrow structure in mice in vivo. Lineage 
mapping studies in mice identified overlapping subsets of mesenchymal progenitors based 
on the activity of developmental specific promoter activity (nestin and prx1 promoters) [44, 
197]. These bone marrow perisinusoidal mesenchymal stem cells are an important 
component of the niche and contribute to the formation of this niche [31]. Explanted MSC 
have the capacity to generate bone [184] and to organize and reconstitute the hematopoietic 
niche in vivo [31, 32, 44]. The hTERT-immortalized MSC that were used for our study display 
high PRRX1 RNA levels (data not shown) and fulfill progenitor-defining criteria [129], but to 
which extent they correspond to these murine mesenchymal stem cells has not been 
characterized. Nevertheless, our platform provides stimulating insights into leukemia-specific 
functional interaction patterns and the basis to profile functional differences between MSC 
that are derived from different individuals or at different times of disease progression.  
 
Both interactions by direct contact and soluble factors, including microvesicles [198], are 
important and build a unique leukemia-supporting network. For ALL cells, adhesion 
molecules such as VE-cadherin [199] and soluble factors such as SDF-1 or IL-7 have been 
implicated [72, 78]. Importantly, we detect individual patterns of stromal support using the 
same hTERT-MSC line with primary ALL cells from different patients. These differences could 
be due to the activation of MSC by leukemia cells or the specific dependence of leukemia 
cells from a given signal. We detected reproducible effects by interference with 16 candidate 
genes. A subset of ALL cases depended most strongly on paracrine signaling via VEGFC. 
This is consistent with a report of the activity of VEGF inhibitors on ALL cells [72]. Both 
autocrine and paracrine effects could be involved, as it was shown that leukemia cells can 
secrete VEGF [200, 201]. Our data suggest that this platform will be useful to identify 
leukemia-specific interaction patterns with stromal cells. 
Metabolic reprogramming is a dominant feature of cancer cells [202]. Metabolite profiling of 
leukemia cells confirmed their increased biosynthetic activity [203]. This requires an 
adaptation of cancer cells to produce sufficient anti-oxidants such as NADPH [204] and 
reduced glutathione [202]. Here we show that stromal Basigin (BSG/CD147), a 
multifunctional cell surface protein, is required for specific metabolic support of leukemia 
samples that depend on glutathione for survival. BSG has been shown to interact functionally 
with different effectors, including metalloproteinases and monocarboxylate transporters. As 
subunit of the lactate/H+ symporters MCT1 and 4, BSG regulates the export of lactic acids 
[193]. As an alternative, we also considered the interaction of BSG with amino acid 
transporters via SLC3A2 (CD98h) [194], given a recent report showing the dependence of 
chronic lymphoblastic leukemia cells from stromal cystine-cysteine metabolism for 
glutathione synthesis [115]. Functional profiling by RNA interference with putative BSG 
interacting genes clustered ALL cases in two groups, one cluster corresponding to samples 
that depend on stromal BSG. RNA interference with SLC3A2, the heavy subunit of 
heteromeric aminoacid transporters HAT [205] mimicked the loss of stromal BSG most 
  
 
 
closely. Together with SLC7A11, SLC3A2 forms a HAT that can exchange cystine for 
glutamate, suggesting that stromal cystine metabolism could be critical for ALL. 
Our data support a model in which BSG is essential to mediate import of cystine to MSC as a 
first step. By quantitative PCR we confirmed very strong detection of SLC7A11 in MSC and 
weak detection in ALL cells (data not shown), which suggests that ALL cells may have a 
limited capacity to import cystine. Indeed, cystine import and metabolism to cysteine in 
stroma is required for ALL support, because loss of stromal BSG is not rescued by 
supplementation with cystine but with cysteine. Depletion of cystine affected BSG-dependent 
ALL in a dose dependent manner, which demonstrates that the cysteine supply by MSCs is 
limiting. Whether stromal BSG/SLC3A2 is required for cysteine export cannot be finally 
concluded based on our data. Cysteine is a rate limiting substrate for GSH synthesis 
together with glycine and glutamine. Because reduced cysteine is rapidly oxidized in the 
microenvironment, constant supply for ALL cells appears to be needed for the metabolic 
control of the redox state in ALL. Indeed, we show that interference with the cystine-cysteine 
supply is associated with a significant decrease of GSH and concomitant increase in ROS, 
which results in marked induction of apoptosis only in ALL samples that are dependent of 
this stromal function of BSG/SLC3A2. Our results suggest that major underlying differences 
exist in ALL with respect to the vulnerability to cysteine depletion. This phenotype is not 
associated with a classical clinical risk factor and does not correlate with marked differences 
in HAT levels on ALL cells seen on gene expression profiles (data not shown). The 
underlying mechanism is intriguing, and it is possible that cysteine dependent ALL have 
defects in alternative pathways to synthesize anti-oxidants.  
Taken together, our data illustrate that distinct networks of interactions between leukemia 
cells and MSC exist, which has implications for the development of targeted therapies. 
Metabolic interactions may constitute a predominant function of the leukemia niche, as 
reflected by the selective dependence on stromal cysteine to control ROS in leukemia cells. 
This metabolic vulnerability could be targeted using inhibitors of the anti-oxidant synthesis. 
Similarly, the dependence of ALL on asparagine provides the basis for therapy with 
asparaginase, which can also be influenced by the metabolic activity of the niche [116]. As 
lesions in metabolic networks in leukemia are being increasingly identified, it will be essential 
to understand their implications in the context of the leukemia niche. Functional profiling 
approaches such as the one shown here will contribute to detect vulnerable leukemia 
specific features in an individualized manner. 
 
 
MATERIAL and METHODS 
 
Cell culture 
Human hTERT-immortalized primary bone marrow MSCs were provided by D. Campana (St 
Jude Children’s Research Hospital, Memphis, Tennessee) and maintained at 37°C and 5% 
CO2 in RPMI-1640 medium supplemented with L-glutamine, penicillin/streptomycin, 10% 
fetal bovine serum (Hyclone) and 1µM Hydrocortisone. HS-5 cells were purchased from 
ATCC (CRL-11882) and maintained at 37°C and 5% CO2 in Dulbecco's Modified Eagle's 
Medium supplemented with L-glutamine, penicillin/streptomycin and 10% fetal bovine serum 
(Hyclone). Cystine, cysteine, GSH and N-acetylcysteine (all from Sigma) and zVAD-FMK 
(Promega) as well as the VEGFR inhibitors axitinib and cediranib (both from Axon Medchem) 
  
 
 
were used at indicated concentrations. MSC and ALL cells in co-culture were cultivated in 
AIM-V medium (Life technologies) with a ratio of 1:10, for HS-5 co-cultures a ratio of 1:20 
was used. Transwells® of 0.4µ pore size (Corning) were used for the transwell assays.  
For the cystine depletion experiment, cystine depleted medium (Sigma) was supplemented 
with L-glutamine and penicillin/streptomycin (without FCS); the control media was RPMI-
1640 medium supplemented with L-glutamine, penicillin/streptomycin (without FCS). 
 
Flow cytometry 
Analyses of ALL cell viability in co-culture with MSCs were performed as described 
previously [129, 131] using 7-AAD (BD Pharmingen) and FITC-tagged anti-human CD45 or 
RPE-tagged CD19 (both AbD Serotec). 
 
Glutathione and ROS measurements 
Glutathione levels in co-culture were measured using the GSH-Glo™ Glutathione Assay from 
Promega according to the manufacturer’s instructions. Shortly, ALL cells were cultivated with 
MSC cells for 3 days and separated by trypsinization. ALL cells were replated in AIMV 
medium to enable MSC cells to adhere to plates for one and a half hour. ALL cells were then 
removed, plated into 96 well plates, and GSH levels were measured on a Synergy HT 
(Biotek) reader. For measurements of ROS levels, cells were stained after 3 days in co-
culture or 48h in suspension culture with 20µM DCF-DA (Sigma) for 2 hours at 37°C / 5% 
CO2 and processed for flow cytometry analysis. 
 
Microscopy 
Co-cultures of MSC and ALL cells were stained with CyQUANT® Direct Cell Proliferation 
Assay (Life Technologies, C35011 and C35012) using a modified protocol. In brief, 
component A (diluted 1:375) and component B (diluted 1:75) were added to the cells for 45 
minutes at 37°C and 5% CO2. Staining solution was r emoved and AIM-V medium with 
compound B (diluted 1:100) was added for 1 hour at 37°C and 5% CO2 prior imaging. 
Images were taken on the ImageXpress Micro microscope from Molecular Devices with a 
CoolSNap HQ camera from Photometrics and a 10x Plan Fluor objective from Nikon with 0.3 
NA.  Image acquisition was set to cover more than 50% of each well in a total of 9 images 
(Fig. 2A). For image analysis, images were first segmented using the CellProfiler software 
[180] and distinction of viable ALL cells from dead ALL cells as well as MSCs was 
implemented in a machine learning tool for high-content analysis (Advanced Cell Classifier-
ACC) [181]. An ‘a trous’ wavelet transform-based spot detection algorithm [179] was 
implemented in the MatLab software and was built into the CellProfiler framework. For each 
detected spot on an image, over 50 intensity and texture-based features were extracted. The 
list of extracted features, CellProfiler pipelines, and the parallelization code are accessible at 
www.highcontentanalysis.org. For correct assignment of ALL cells, the Advanced Cell 
Classifier program [181] used the random forest classification method for all experiments 
[182]. 
 
Patient samples and xenograft model 
ALL cells were recovered from cryopreserved anonymized bone marrow aspirates from 
patients enrolled in the ongoing ALL-BFM 2000 study of ALL-REZ-BFM 2002 who had given 
informed consent in accordance with the Declaration of Helsinki. Samples were anonymized 
with labels that refer to the clinical risk stratification. Depending on the MRD result during 
induction therapy (MRD1 + 2) and during consolidation therapy (MRD3), patients are defined 
here as standard risk (SR) if MRD1 + 2 were negative, high risk (HR) if MRD1 + 2 were 
positive less than or equal to 10−3, and VHR if HR patients were still positive for MRD3 
(suppl. Table 1). MNR cases represent relapsed ALL cases from the ALL-REZ-BFM 2002 
  
 
 
study. Cases are anonymized with a label according to the risk group and with a unique 
number. Cryopreserved ALL cells were transplanted intrafemorally to NSG mice as 
described (Schmitz et al, leuk lymph). Leukemia progression was monitored by flow 
cytometry with human CD45 and CD19 antibodies (AbD Serotec). Leukemic cells were 
isolated from the spleen and cryopreserved. 
 
siRNA Screen and siRNA validation assays 
The custom library (ON-TARGETplus siRNAs with a pool of 4 siRNAs per well with a final 
concentration of 30nM) was purchased from Thermo Fisher Scientific. For all validation 
experiments ON-TARGETplus pooled siRNAs (final concentration 40nM) were used. 
Reverse transfection was performed using the INTERFERin® reagent from Polyplus-
Transfection SA according to the manufacturer’s instructions. For all validation assays, RT-
PCR was performed to check for the downregulation at mRNA level of the targeted genes.  
 
Statistical analysis 
Statistical significance was analyzed by the Mann-Whitney test comparing BSG/SLC3A2 
sensitive patient group with the BSG/SLC3A2 non-sensitive patient group. P-values of <0.05 
were considered statistically significant. Histograms and plots were generated using the 
Prism software (GraphPad), except the clustered Heatmap in Figure 4 which was generated 
using MATLAB (MathWorks). 
 
Western blot 
Whole-cell extracts were prepared from 1 x 106 cells using radioimmunoprecipitation assay 
(RIPA) buffer (50 mM Tris-Cl, pH 6.8, 100 mM NaCl, 1%Triton-X-100, 0.1% SDS) 
supplemented with complete mini protease inhibitor cocktail (Roche Applied Sciences) for 20 
minutes on ice. After SDS-PAGE, proteins were blotted onto nitrocellulose membranes. 
Membranes were blocked in 5% non-fat dry milk and incubated with primary antibodies in 3% 
bovine serum albumin (Sigma). ITGB1 antibody (Abnova, clone MEM-101A) was diluted 
1:1000. Horseradish peroxidase-labeled goat anti-rabbit or anti-mouse antibodies were used 
for signal detection with chemiluminescence substrate (Pierce) and direct scanning 
(Fujicolor).  
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Discussion 
 
Here I describe the development of a high-content screening platform to study interactions 
between primary childhood acute lymphoblastic leukemia (ALL) cells and mesenchymal 
stromal cells derived from human bone marrow. To our knowledge this is the first report of a 
high throughput system using a co-culture system with primary ALL cells. The system 
described here has many relevant potential applications. Besides its potential for functional 
genetic studies, it provides an entirely new dimension for preclinical drug testing. Indeed, this 
platform is currently used in our laboratory to investigate synthetic lethal combinations of 
drugs in different ALL subtypes. Studies can be performed on stable co-cultures with viable 
primary ALL cells very effectively. I show here the functional importance of intercellular 
interactions between leukemia and stromal cells. Interestingly, patient sample specific 
support patterns were identified. Moreover, the system has enabled the identification of 
relevant combinations of new agents in resistant ALL cases, which further demonstrates the 
usefulness of this platform for preclinical studies.  
 
 
A two dimensional model of the leukemia microenvironment constitutes a useful 
platform for functional studies 
 
While most primary B-ALL cells rapidly undergo cell death in suspension cultures, hTERT 
immortalized primary human bone marrow stromal cells (MSC) support most B-ALL cases 
that we evaluated in vitro. This MSC cell line retains contact inhibition, has a normal 
karyotype, and has retained the capacity to differentiate to adipocytes or osteoblasts in vitro 
[129]. An essential component of the bone marrow niche are the skeletal stem cells, which 
represent single cells able to regenerate a heterotopic bone organ or an ossicle in vivo [31]. 
Mesenchymal stroma cells isolated from the bone marrow have the capacity to regenerate a 
functional human hematopoietic microenvironment upon xenotransplantation [184]. However, 
these MSCs consist of heterogeneous cell populations and controversies exist regarding the 
niche functions of different identified subpopulations [31]. The use of reporter systems for 
lineage mapping of specific subpopulations in mouse models allowed characterizing more 
precisely the niche functions of MSC subpopulations in mice. Subpopulations of the 
endosteal niche such as osteoblasts and their progenitors were compared to subpopulations 
from the perivascular niche (endothelial cells, CXCL12-abundant reticular (CAR) cells, and 
mesenchymal stem and progenitor cells (including Nestin-GFP+ cells)) in their HSC 
supportive functions [197]. The subpopulation of mesenchymal stem and progenitor cells 
expressing Prx1, which is a transcription factor expressed early during limb bud mesoderm 
development, proved to be essential to support HSC in mice. We observed in our gene 
expression analysis a high expression of the human homologue of Prx1, PRRX1, in MSCs. 
This indicates that at least some overlap exists between human MSC cells and the mouse 
HSC niche. However, models to better characterize the functions of MSCs in the human 
HSC niche are required. It will be important to develop models to study the pathways that we 
have identified in vivo. As a first step we will consider the development of heterotopic bone 
formation models [147, 148] . The advantage of this system is to use human xenografts with 
the possibility to genetically modify both compartments (heterotopic bone and leukemic 
cells). 
  
 
 
Taken together, we use MSCs that have a phenotype that is partially overlapping with MSCs 
that were described to be essential in the HSC mouse niche and leukemic cells able to 
reflect human disease biology. With this co-culture system, we are able to model intercellular 
interactions between leukemic cells and cells from the bone marrow microenvironment. 
 
 
The identification of individual differences in intercellular interactions between 
leukemia and stroma has implications for translational research 
 
We conducted the first study by investigating the supportive functions of stromal candidate 
proteins for primary B-ALL cells. We could not identify a common denominator of the support 
of leukemia cell survival by MSCs using our candidate gene approach. Instead, we observed 
individual support patterns. A subset of ALL cases depended most strongly on stromal 
VEGFC secretion. As a proof of concept, the sensitivity of samples to VEGFC RNA 
interference correlated with the sensitivity to two different small molecule inhibitors of VEGF 
receptors, suggesting that this approach may identify targets for individually tailored 
therapeutic intervention. Inhibition of VEGF using the small molecule inhibitors SUI1498 or 
CBO-P11 inhibited the proliferation only of 3 out of 4 ALL cases that had been expanded on 
stroma [72], validating our observation that some patient samples do rely on VEGF signalling 
and some do not. A second predominant hit in this experiment was BSG, which clearly 
identifies a subgroup of patients that are very sensitive to interference this cell surface 
protein, as we will discuss below. One of the most important observations in this work is the 
fact that samples from different patients depend on different cues in this model. This principle 
has important implications on the way to approach preclinical testing in a translational 
perspective. Relevant studies will have to take this important heterogeneity into account. A 
preclinical platform that can capture such difference should therefore be an important asset 
to triage among different therapeutic options using directly relevant patient material.  
 
Identification of bidirectional crosstalks between leukemic and stromal cells 
 
Beside VEGFC and BSG, we identified other interesting pathways with a potential role for a 
leukemia niche function.  
 
Although, the NOTCH pathway is very prominent for cell intrinsic transformation of T-cell  
ALL [95], the role of NOTCH in cell to cell interactions in the leukemia niche remains to be 
addressed. To assess the role of NOTCH on stromal cells, we downregulated all 4 NOTCH 
members, NOTCH 1, 2, 3 and 4. 4 out of 10 patient samples tested in the co-culture showed 
a significant decrease in ALL cell viability when stromal NOTCH4 was targeted. To our 
knowledge, there was only one study which investigated the role of the NOTCH pathway in 
co-cultures with B-ALL cells [98]. In this study, NOTCH3 and 4 were reported to play a role in 
B-ALL cell support. Interestingly, NOTCH1, 2 and 3 were found to be expressed on bone 
marrow derived MSCs before co-culture. After co-culture with B-ALL cells, expression of 
NOTCH2 was found to be downregulated and expression of NOTCH 3 and 4 was 
upregulated on MSCs. The addition of NOTCH 4 antibodies to co-cultures showed the most 
dramatic effect manifested by the loss of support for B-ALL cells. Based on these preliminary 
results, the role of NOTCH should be further investigated in this context.  
  
 
 
Similarly, we were interested in assessing the role of the Wnt pathway in B-ALL, because of 
its very prominent role in the HSC niche [59, 206]. We detected some reproducible effects 
when interfering with several genes of this pathway in MSC. We selected 5 genes for further 
validation, namely CDH2, FZD6, FZD7, CTNNB1 and WISP1. CDH2, FZD6 and 7 are 
receptors known to activate the pathway. CTNNB1 is a central key player of the canonical 
Wnt pathway and WISP1 (WNT1 inducible signalling protein 1) is another downstream 
regulator of the pathway. In addition, we included proteins that, although not directly 
connected to Wnt signaling, were reported to be associated with some key proteins in the 
investigated pathway, namely PDGFRB, TGFB2 and THBS1 (see Fig.22). Five out of 10 
patient samples tested show a significant decrease in ALL cell viability when these genes are 
targeted. Therefore this pathway will be included in follow-up projects as well. 
 
 
 
Figure 22. WNT pathway related proteins-Network generated by the STRING database 
 
 
 
The candidate mediator of stroma interactions BSG has several functional roles that 
could be of relevance in this context 
 
In leukemia, BSG expression on malignant cells was reported to correlate with patient 
outcome and increased risk of relapse [207, 208]. Expression of BSG on other cancer cells is 
associated with drug resistances [209-211]. It is therefore likely that this protein drives 
important pathways in cancer. In the RNA interference screen, I identified a strong 
dependence phenotype of ALL subsets on the function of stromal Basigin. This protein could 
have different mode of actions. A recent report linked BSG to the function of 
monocarboxylate transporters [193, 212]. These transporters, which are formed by MCT1 or 
MCT4, are important to modulate the flux of substrates such as lactate and pyruvate. We first 
explored this possibility in several ways. We did not see detectable changes in intracellular 
and extracellular lactate concentration upon modulation of stromal BSG nor did lactate 
supplementation affect ALL survival in our in vitro assay. Furthermore downregulation of 
stromal MCT1 or of MCT4 did not affect the same ALL samples in terms of their survival. In 
addition an inhibitor of MCT1 did show activity in co-cultures. Therefore, 16 genes that were 
implicated in other experimental models were tested using our platform. Interestingly, the 10 
ALL cases that we tested on this platform clustered in two distinct subgroups based on the 
functional interference data with these 16 genes, separating the patients based on 
  
 
dependence from stromal BSG (Manuscript 2 Figure 18). Among the genes showing activity 
in the BSG cluster, we found several Matrix metalloproteinases (MMP). BSG functionally 
interacts and triggers MMP, and is therefore also termed EMMPRIN [213-216]. Matrix 
metalloproteinases (MMP) are involved in cancer progression and metastasis, through 
degradation of the extracellular matrix [217]. Moreover, BSG is involved in adhesion 
processes through homotypic interactions (for example in platelets [218]) or through 
interaction with LFA-1 [219] and controls the formation of invadipodia [220]. Moreover, BSG 
is favouring anchorage independent growth due to stimulation of hyaluronan production 
[221]. BSG knockout mice are not fertile as BSG is important in spermatogenesis and 
implantation of embryos in the endometrium due to its invasion and adhesion controlling 
properties [222, 223]. For instance, invasion of immune cells into the CNS is mediated by 
BSG [224, 225].  
 
However, we first focused on the potential functional interaction with SLC3A2 and a role for a 
metabolic crosstalk with leukemia. BSG was shown to interact with the solute carrier, 
SLC3A2 in mass spectrometry experiments in MCF7 (breast adenocarcinoma cells) and in 
HT1080 (fibrosarcoma cells) [194]. RNA interference with SLC3A2 mimicked the effect of 
BSG knockdown most closely. This became the focus of validations that are described in the 
manuscript 2. We could demonstrate that this was essential for cystine import by MSC and 
metabolism to cysteine, an important substrate for ALL cells. Whether BSG interacts 
moleculary directly with SLC3A2 is the focus of current investigation. BSG was describe to 
engender homotypic interactions [216, 218, 226]. However using the same antibodies that 
were reported in these publications to inhibit such interactions, we did not detect a decrease 
of ALL viability in our co-culture system. Alternatively, BSG could trigger signalling pathways 
through interaction with other ligands, such as interactions with integrins, downstream 
kinases (MAPK, AKT, ERK) or cyclophilins [213, 221, 227, 228]. 
 
 
Some but not all ALL cases require metabolic support via BSG/SLC3A2 
 
By the time we identified SLC3A2 as a candidate to explain the selective sensitivity of ALL to 
BSG mediated stromal function, the importance of stromal metabolism of cystine was 
reported in a model of chronic lymphoblastic leukemia [115]. Here we independently showed 
that some ALL samples are strongly dependent on cysteine supply by stromal cells and that 
this required SLC3A2 import of cystine in MSC. Cysteine is used to synthesize glutathione 
(GSH), an important cellular anti-oxidant (the GSH pathway is depicted in Fig. 23) composed 
of the three amino acids glutamine, cysteine and glycine [229]. Because of the instability of 
cysteine, cystine, the stable dimeric form of cysteine, is routinely added to cell culture 
medium formulations used for in vitro cultures. Our data suggest that ALL cells have a 
restricted capacity to import cystine due to low expression levels of the co-transporter 
SLC7A11 (data not shown) and thus require constant supply of the unstable amino acid 
cysteine for their GSH synthesis. Indeed, stromal supply of cysteine restored the GSH and 
ROS levels detected in ALL cells (highlighted in red in Fig.23). GSH is synthesized by  
γ-glutamylcysteine synthetase (γ-GCS), the rate-limiting enzyme of the synthesis, and 
glutamyl synthase (GS) [230]. Detoxification of a variety of electrophilic compounds and 
peroxides occurs via catalysis of GSH by glutathione S-transferases (GST) and glutathione 
peroxidases (GSH-PX) [229]. GSH is oxidized to generate GSSG, which is recycled back to 
GSH by the action of glutathione reductase (GSSG-RD) at the expense of reduced 
nicotinamide (NADPH/H+) [230]. 
Figure 23. Model of the GSH pathway. Adapted from [230].A major source of H2O2 is the biochemical 
conversion of superoxide anion (O2-•) by the action of superoxide dismutase (SOD).  
The molecular mechanisms underlying the differences between different ALL samples with 
respect to their dependence on stromal BSG will be an interesting new avenue for future 
exploration. One possibility would be differences in the expression of limiting enzymes in the 
GSH pathway. Our gene expression profiles did not show a correlation of GST or GSH-PX 
levels to the sensitivity pattern to cysteine depletion. However, there is a trend towards lower 
mRNA levels of the catalytic subunit of γ-glutamylcysteine synthetase in sensitive cases 
(data not shown), which requires further confirmation. Mutations or differential activities in 
metabolic enzymes involved in the GSH pathway could be responsible for the differential 
metabolic activities. Metabolomic studies will be conducted to identify suggestive differences 
in the metabolism of these patients. Despite the fact that high GSH levels in ALL cells were 
suggested to be related to poor outcome [231] and to be associated with an increased risk of 
relapse [232], we could not detect a direct association this in vitro phenotype with classical 
clinical risk stratification in these 10 patients. This may however be due to the small sample 
size for such comparisons.  
Collectively, the experiments presented here establish our high-content platform as we could 
identify and validate different modalities of intercellular interactions. The data supports the 
use of this model for a large scale study, including more patients and testing a much larger 
number of genes. However, already the pathways that we identified here will constitute a 
solid basis for more investigations. The fact that we identify clear subsets in ALL with a 
pronounced dependence on signalling by VEGF is of immediate clinical relevance. 
Furthermore, the identification of a phenotype of metabolic interdependence for protection 
from oxidative stress could also be amenable to specific therapeutic targeting. Finally the 
development of this platform opens new dimension for combinatorial testing of primary ALL 
cells with new agents, which is of outmost importance in this field.   
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Suppl. Table 1. ALL patient characteristics
Patient Immunology Age at initial diagnosis Sex
Prednisone 
response
Risk 
group Relapse Survival
Leukocye 
count
Blasts 
periph % Additional information
HR-03 Common-ALL 16.9 f PGR HR no yes 13300 78 CNS, t(9;22), hhd
MNR-01 Pre-B-ALL 9.6 f PGR MNR yes no 2346 na TP53 del.
MNR-03 Pre-B-ALL 4.3 f PPR MNR yes no 64410 na
MNR-04 Pre-B-ALL 9.8 m PPR MNR yes no 5040 na
MNR-07 Pre-B-ALL 12.6 f PPR MNR yes no 27945 na t(4;11)
MNR-09 Pre-B-ALL 3.3 m PPR MNR yes no 250 na
MNR-10 Pre-B-ALL 9.7 m PPR MNR yes no 4165 na
SR-02 Pre-B-ALL 12.1 m PGR SR no yes 447000 94 Amplification AML1, t(1;19)
SR-04 Common-ALL 3.6 f PGR SR no yes 10600 42  t(1;19)
SR-09 Common-ALL 5.5 f PGR SR yes yes 317400 na 
SR-10 Common-ALL 7.3 m PGR SR no yes 17050 65
SR-11 Common-ALL 6.1 m PGR SR yes yes 66600 87 CNS
SR-13 Common-ALL 4.1 f PGR SR no yes 21000 na 
VHR-01 Common-ALL 14.1 m PPR VHR yes, 2x no 6300 13 early relapse, t(17;19)
VHR-02 Common-ALL 12.8 f PPR VHR yes yes 79600 68
VHR-03 Common-ALL 17.1 m PPR VHR no no 20100 78 TRM
VHR-04 Common-ALL 5.7 f PGR VHR no yes 45700 97
VHR-06 Pre-B-ALL 17.6 m PGR VHR yes no 8000 73 complex karyotype, t(1;19), t(12;2)
VHR-07 Pro-B-ALL 11.6 m PPR VHR no yes 100000 99 t(4;11)
VHR-10 Common-ALL 14.4 f PPR VHR no yes 150000 89
VHR-11 Pre-B-ALL 3.1 m PGR VHR yes no 16000 na DS
VHR-12 Pre-B-ALL 15.3 f PPR VHR no yes 7412 92
VHR-15 Pre-B-ALL 13.2 m PGR VHR yes yes 2900 60 deletion 9p
VHR-23 Common B-ALL na na PGR VHR yes na na na t(17;19)
VHR-28 Common-B-ALL na f na VHR yes na na na
Risk group assessed accordingly on the MRD result:
patients are defined as standard risk (SR) if MRD1 + 2 were negative, high risk (HR) if MRD1 + 2 were positive less than or equal to 10−3, and VHR if HR patients were still positive for MRD3
MNR stand for morphological non-responder, patients with relapse ALL
CNS:disease spread into central nervous system
hhd: hyperdiploid
TRM: treatment-related mortality 
na: not available
Suppl. Table 2. Mass spectrometry identified proteins
Entrez gene 
symbol
Entrez 
Gene ID
CD 
annotation Description
Number of 
distinct 
peptides 
Assignment 
to 
membrane
UniProtKB/Swiss-
Prot ID
 UniProtKB/Swiss-
Prot AC2
ABCA8 10351 na 180 kDa protein,Isoform 1 of ATP-binding cassette sub-family A member 8,Isoform 2 of ATP-binding cassette sub-family A member 8,ABCA8 protein1 1 ABC 8_HUMAN O94911
ACE 1636 CD143 Angiotensin-converting enzyme, somatic isoform precursor1 1 ACE_HUMAN P12821
ACTA2 59 na Actin, aortic smooth muscle,Actin, alpha skeletal muscle,Actin, cytoplasmic 1,Actin, cytoplasmic 2,Actin, alpha cardiac muscle 1,Actin, gamma-enteric smooth muscle,Actin alpha 1 skeletal muscle protein,Actin, alpha 1, skeletal muscle,Actin, alpha 1, skelet1 0 BCC8_HUMAN Q09428
ACTB 60 na Actin, cytoplasmic 1,Actin, cytoplasmic 2,Actin-like protein (Fragment),Actin-like protein (Fragment),22 kDa protein,16 kDa protein2 0 ACTB_HUM N P60709
ADAM15 8751 na ADAM 15 precursor,a disintegrin and metalloproteinase domain 15 isoform 4 preproprotein,a disintegrin and metalloproteinase domain 15 isoform 5 preproprotein,a disintegrin and metalloproteinase domain 15 isoform 3 preproprotein,a disintegrin and metallopro1 1 PCTK3_HUMAN Q07002
ADAM17 6868 CD156b Isoform B of ADAM 17 precursor,Isoform A of ADAM 17 precursor1 1 ADA17_HUMAN P78536
ADAM9 8754 na Isoform 1 of ADAM 9 precursor,Isoform 2 of ADAM 9 precursor,ADAM9 protein1 1 PCY1A_HUMAN P49585
ADCY9 115 na Adenylate cyclase type 9 2 1 ADCY9_HUMAN O60503
AGGF1 55109 na Isoform 1 of Angiogenic factor with G patch and FHA domains 11 0 AGGF1_HUMAN Q8N302
AHSG 197 na Alpha-2-HS-glycoprotein precursor,29 kDa protein1 0 FETUA_HUMAN P02765
ALB 213 na ALB protein,Isoform 2 of Serum albumin precursor,Isoform 1 of Serum albumin precursor2 0 ALBU_HUMAN P02768
ALCAM 214 CD166 Isoform 1 of CD166 antigen precursor,65 kDa protein,62 kDa protein22 1 A AM7_HUMAN Q9H2U9
ALDOA 226 na Fructose-bisphosphate aldolase A,45 kDa protein1 1 RED1_HUMAN P78563
ALPL 249 na Alkaline phosphatase, tissue-nonspecific isozyme precursor11 0 PPBT_HUMAN P05186
ALS2CL 259173 na CDNA FLJ44541 fis, clone UTERU30054601 0 AL2CL_HUMAN Q60I27
ANKFY1 51479 na ankyrin repeat and FYVE domain containing 1 isoform 21 0 ANFY1_HUMAN Q9P2R3
ANPEP 290 CD13 Aminopeptidase N 8 1 AMPN_HUMAN P15144
ANTXR1 84168 na Isoform 1 of Anthrax toxin receptor 1 precursor,Isoform 2 of Anthrax toxin receptor 1 precursor,Isoform 3 of Anthrax toxin receptor 1 precursor,Anthrax toxin receptor/neuroblastoma fusion protein transcript variant 3,Anthrax toxin receptor/neuroblastoma fu1 1 ANTR1_HUMAN Q9H6X2
ASAM 79827 na adipocyte-specific adhesion molecule2 1 ASAM_HUMAN Q9H6B4
ATP1B3 483 CD298 Sodium/potassium-transporting ATPase subunit beta-3,similar to Sodium/potassium-transporting ATPase subunit beta-3 (Sodium/potassium-dependent ATPase beta-3 subunit) (ATPB-3) (CD298 antigen) isoform 1,similar to Sodium/potassium-transporting ATPase subunit3 1 AT1B3_HUMAN P54709
AUTS2 26053 na Isoform Long of Autism susceptibility gene 2 protein,Isoform Short of Autism susceptibility gene 2 protein1 0 AUTS2_HUMAN Q8WXX7
AXUD1 64651 na Axin-1 up-regulated gene 1 protein1 0 AXUD1_HUMAN Q96S65
BAT2D1 23215 na BAT2-iso,HBxAg transactivated protein 21 0 PIGO_HUMAN Q8TEQ8
BRDG1 26228 na Signal-transducing adaptor protein 11 0 STAP1_HUMAN Q9ULZ2
BSG 682 CD147 Isoform 2 of Basigin precursor,Isoform 1 of Basigin precursor,46 kDa protein, neurothelin4 1 BASI_HUMAN P35613
BTN3A3 10384 na Butyrophilin subfamily 3 member A3 precursor,Butyrophilin subfamily 3 member A2 precursor,Isoform 2 of Butyrophilin subfamily 3 member A1 precursor,butyrophilin, subfamily 3, member A3 isoform b,Isoform 1 of Butyrophilin subfamily 3 member A1 precursor,But1 1 RS11_HUMAN P62280
C14orf78 113146 na similar to AHNAK nucleoprotein isoform 1 isoform 1,similar to AHNAK nucleoprotein isoform 12 1 AHNK2_HUMAN Q8IVF2
C19orf31 404664 na Uncharacterized protein C19orf311 0 na na
C5 727 na Complement C5 precursor 1 0 ARTN_HUMAN Q5T4W7
CACNA1C 775 na Isoform 1 of Voltage-dependent L-type calcium channel subunit alpha-1C,Isoform 2 of Voltage-dependent L-type calcium channel subunit alpha-1C,Isoform 24 of Voltage-dependent L-type calcium channel subunit alpha-1C,Isoform 28 of Voltage-dependent L-type cal1 1 CAC1C_HUMAN Q13936
CACNA2D1 781 na Dihydropyridine receptor alpha 2 subunit,Dihydropyridine-sensitive L-type calcium channel subunits alpha- 2/delta precursor3 1 CAC2D_HUMAN P54289
CASQ2 845 na Calsequestrin-2 precursor 1 0 CASQ2_HUMAN O14958
CD109 135228 CD109 Isoform 1 of CD109 antigen precursor,Isoform 3 of CD109 antigen precursor,Isoform 4 of CD109 antigen precursor4 1 CD109_HUMAN Q6YHK3
CD151 977 CD151 CD151 antigen 4 1 CD151_HUMAN P48509
CD248 57124 CD248 Isoform 1 of Endosialin precursor2 1 CD248_HUMAN Q9HCU0
CD276 80381 CD276 Isoform 2 of CD276 antigen precursor,Isoform 1 of CD276 antigen precursor,Isoform 3 of CD276 antigen precursor,Isoform 4 of CD276 antigen precursor,60 kDa protein2 1 CD276_HUMAN Q5ZPR3
CD44 960 CD44 Isoform 12 of CD44 antigen precursor,Isoform CD44 of CD44 antigen precursor,Isoform 4 of CD44 antigen precursor,Isoform 10 of CD44 antigen precursor,CD44 molecule,Isoform 9 of CD44 antigen precursor,Isoform 3 of CD44 antigen precursor,Isoform 7 of CD44 ant6 1 CD44_HUMAN P16070
CD55 1604 CD55 Decay-accelerating factor splicing variant 4,Isoform 1 of Complement decay-accelerating factor precursor,Isoform 2 of Complement decay-accelerating factor precursor,Decay-accelerating factor splicing variant 5,CD55 molecule, decay accelerating factor for c3 1 DAF_HUMAN P08174
CD59 966 CD59 CD59 glycoprotein precursor 23 1 CD59_HUMAN P13987
CD63 967 CD63 CD63 antigen,Lysosome-associated membrane protein-3 variant,CD63 antigen isoform B,14 kDa protein,15 kDa protein,13 kDa protein2 1 CD63_HUMAN P08962
CDC42 998 na Isoform 2 of Cell division control protein 42 homolog precursor2 0 BCL3_HUMAN P20749
CDH2 1000 CD325 Cadherin-2 precursor,97 kDa protein2 1 CADH2_HUMAN P19022
CDSN 1041 na Corneodesmosin precursor,S protein,Corneodesmosin1 0 BFSP2_HUMAN Q13515
CFP 5199 na Properdin precursor,50 kDa protein1 0 PROP_HUMAN P27918
CHD9 80205 na Isoform 1 of Chromodomain-helicase-DNA-binding protein 9,Isoform 2 of Chromodomain-helicase-DNA-binding protein 9,Isoform 3 of Chromodomain-helicase-DNA-binding protein 91 1 CHD9_HUMAN Q3L8U1
CLIC4 25932 na Chloride intracellular channel protein 41 0 CLIC4_HUMAN Q9Y696
CORIN 10699 na Atrial natriuteric peptide-converting enzyme1 1 CORIN_HUMAN Q9Y5Q5
CPM 1368 na Carboxypeptidase M precursor 3 0 CAH1_HUMAN P00915
CRELD1 78987 na Isoform 2 of Cysteine-rich with EGF-like domain protein 1 precursor,Isoform 1 of Cysteine-rich with EGF-like domain protein 1 precursor1 1 CREL1_HUMAN Q96HD1
CSHL1 1444 na 23 kDa protein,26 kDa protein 1 1 CSHL_HUMAN Q14406
CSRP1 1465 na Cysteine and glycine-rich protein 1,Cysteine and glycine-rich protein 1 variant (Fragment)0 CSRP1_HUMAN P21291
CTGLF1 119016 na Centaurin gamma-like family member 1,similar to centaurin, gamma-like family, member 1 isoform 1,similar to centaurin, gamma-like family, member 1 isoform 3,MRIP2,Centaurin, gamma-like family, member 4,45 kDa protein,Centaurin, gamma-like family, member 3,1 0 CTLF1_HUMAN Q96P64
CTSB 1508 na Cathepsin B precursor 1 0 CATB_HUMAN P07858
CYB5R3 1727 na Isoform 1 of NADH-cytochrome b5 reductase,Isoform 2 of NADH-cytochrome b5 reductase1 0 NB5R3_HUMAN P00387
DAG1 1605 na Dystroglycan precursor 1 1 CCR4_HUMAN P51679
DCD 117159 na Dermcidin precursor 4 0 DCD_HUMAN P81605
DENND1B 163486 na DENND1B protein,DENN/MADD domain containing 1B1 1 DEN1B_HUMAN Q6P3S1
DNA2L 1763 na DNA2 DNA replication helicase 2-like,Isoform 3 of DNA2-like helicase,Isoform 2 of DNA2-like helicase1 0 DNA2L_HUMAN P51530
DTNBP1 84062 na Isoform 1 of Dysbindin,dystrobrevin binding protein 1 isoform c1 0 DTBP1_HUMAN Q96EV8
DVL1 1855 na Dishevelled, dsh homolog 1,dishevelled 1 isoform c,Segment polarity protein dishevelled homolog DVL-1,dishevelled 1 isoform b1 0 DVL1_HUMAN O14640
DYX1C1 161582 na 93 kDa protein,49 kDa protein,cell cycle progression 1 isoform 1,72 kDa protein1 1 DYXC1_HUMAN Q8WXU2
EGFR 1956 na Isoform 1 of Epidermal growth factor receptor precursor,Isoform 2 of Epidermal growth factor receptor precursor,Isoform 3 of Epidermal growth factor receptor precursor,Isoform 4 of Epidermal growth factor receptor precursor5 1 EGFR_HUMAN P00533
EMP3 2014 na Epithelial membrane protein 3 2 1 EMP3_HUMAN P54852
EMR2 30817 CD312 egf-like module containing, mucin-like, hormone receptor-like sequence 2 isoform b,egf-like module containing, mucin-like, hormone receptor-like sequence 2 isoform c,EGF-like module-containing mucin-like hormone receptor-like 2 precursor,Isoform 2 of CD97 1 1 EMR2_HUMAN Q9UHX3
ERBB2 2064 CD340 Receptor tyrosine-protein kinase erbB-2 precursor,erbB-2 isoform b1 1 ERBB2_HUMAN P04626
ERLIN1 10613 na SPFH domain-containing protein 1 precursor,SPFH domain family, member 10 ERLN1_HUMAN O75477
FARP1 10160 na Isoform 1 of FERM, RhoGEF and pleckstrin domain-containing protein 1,FERM, RhoGEF (ARHGEF) and pleckstrin domain protein 1,Isoform 2 of FERM, RhoGEF and pleckstrin domain-containing protein 11 0 FARP1_HUMAN Q9Y4 1
FAS 355 CD95 Tumor necrosis factor receptor superfamily, member 6 isoform 1 variant (Fragment),Isoform 6 of Tumor necrosis factor receptor superfamily member 6 precursor,tumor necrosis factor receptor superfamily, member 6 isoform 3 precursor,Isoform 1 of Tumor necrosi2 1 TNR6_HUMAN P25445
FAT 2195 na Cadherin-related tumor suppressor homolog precursor1 1 COIA1_HUMAN P39060
FBXL20 84961 na F-box and leucine-rich repeat protein 20 variant b1 0 FXL20_HUMAN Q96IG2
FHL2 2274 na Hypothetical protein FHL2,FHL2 isoform 5,Four and a half LIM domains protein 21 0 FHL2_HUMAN Q14192
FLJ21963 79611 na hypothetical protein LOC79611,40 kDa protein1 0 ACSS3_HUMAN Q9H6R
FLJ34931 388939 na hypothetical protein LOC388939 1 0 CB071_HUMAN A6NGG8
Entrez gene 
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UniProtKB/Swiss-
Prot ID
 UniProtKB/Swiss-
Prot AC2
FLNA 2316 na filamin A, alpha,Filamin-A,Filamin A, alpha4 0 FLNA_HUMAN P21333
FN1 2335 na Isoform 1 of Fibronectin precursor,Isoform 3 of Fibronectin precursor,Isoform 5 of Fibronectin precursor,Isoform 6 of Fibronectin precursor,Isoform 7 of Fibronectin precursor,Isoform 8 of Fibronectin precursor,Isoform 11 of Fibronectin precursor,fibronecti23 1 FINC_HUMAN P02751
GAK 2580 na Cyclin G-associated kinase,Cyclin G associated kinase,GAK protein1 0 GAK_HUMAN O14976
GAS2L3 283431 na GAS2-like protein 3,64 kDa protein1 0 GA2L3_HUMAN Q86XJ1
GCC2 9648 na Isoform 1 of GRIP and coiled-coil domain-containing protein 2,Isoform 2 of GRIP and coiled-coil domain-containing protein 2,Ran-binding protein 2-like 41 0 GCC2_HUMAN Q8IWJ2
GGA2 23062 na ADP-ribosylation factor binding protein 2 isoform 21 0 GGA2_HUMAN Q9UJY4
GGTLA1 2687 na Gamma-glutamyltransferase-like activity 1,Isoform 2 of Gamma-glutamyltransferase 5 precursor4 0 GGT5_HUMAN P36269
GJA1 2697 na Gap junction alpha-1 protein,43 kDa protein,KIAA0590 gene product variant (Fragment)1 1 DBP_HUMAN Q10586
GNAI2 2771 na Isoform 2 of Guanine nucleotide-binding protein G(i), alpha-2 subunit,Galphai2 protein,Isoform 1 of Guanine nucleotide-binding protein G(i), alpha-2 subunit,20 kDa protein,19 kDa protein,35 kDa protein,39 kDa protein2 1 GNAI2_HUMAN P04899
GNB1 2782 na Guanine nucleotide-binding protein G(I)/G(S)/G(T) subunit beta 1,Guanine nucleotide binding protein (G protein), beta polypeptide 11 0 GBB1_HUMAN P62873
GPRIN3 285513 na G protein-regulated inducer of neurite outgrowth 31 0 GRIN3_HUMAN Q6ZVF9
GTF2IRD1 9569 na Isoform 1 of General transcription factor II-I repeat domain-containing protein 1,GTF2I repeat domain containing protein 1,Isoform 2 of General transcription factor II-I repeat domain-containing protein 11 0 GT2D1_HUMAN Q9UHL9
hCG_1988300 728638 na similar to Keratin, type II cytoskeletal 8 (Cytokeratin-8) (CK-8) (Keratin-8) (K8) isoform 2,27 kDa protein3 0 K2C8_HUMAN P05787
HLA-A 3105 na HLA class I histocompatibility antigen, A-2 alpha chain precursor,HLA class I histocompatibility antigen, A-69 alpha chain,Leucocyte antigen A precursor3 1 multiple multiple
HLA-B 3106 na HLA class I histocompatibility antigen, B-41 alpha chain precursor,HLA class I histocompatibility antigen, Cw-1 alpha chain precursor,HLA class I histocompatibility antigen, Cw-15 alpha chain precursor,HLA class I histocompatibility antigen, A-33 alpha cha4 1 multiple multiple
HLA-C 3107 na HLA class I histocompatibility antigen, Cw-15 alpha chain precursor,HLA class I histocompatibility antigen, Cw-3 alpha chain precursor,HLA-Cw*0304 (Fragment),HLA class I histocompatibility antigen, B-35 alpha chain precursor,MHC class I antigen,MHC class I2 1 multiple multiple
HSPG2 3339 na Basement membrane-specific heparan sulfate proteoglycan core protein precursor8 0 PGBM_HUMAN P98160
ICAM1 3383 CD54 Intercellular adhesion molecule 1 precursor,Cell surface glycoprotein (Fragment),Cell surface glycoprotein1 1 ICAM1_HUMAN P05362
IGF2R 3482 CD222 Cation-independent mannose-6-phosphate receptor precursor1 1 MPRI_HUMAN P11717
INSRR 3645 na Insulin receptor-related protein precursor1 1 INSRR_HUMAN P14616
ISCU 23479 na Isoform 1 of Iron-sulfur cluster assembly enzyme ISCU, mitochondrial precursor,Isoform 2 of Iron-sulfur cluster assembly enzyme ISCU, mitochondrial precursor1 1 ISCU_HUMAN Q9H1K1
ITGA11 22801 na Integrin alpha-11 precursor 1 1 ITA11_HUMAN Q9UKX5
ITGA3 3675 CD49c Isoform Alpha-3A of Integrin alpha-3 precursor,Isoform Alpha-3B of Integrin alpha-3 precursor6 1 ITA _HUMAN P26006
ITGA5 3678 CD49e Integrin alpha-5 precursor 23 1 ITA5_HUMAN P08648
ITGAV 3685 CD51 Integrin alpha-V precursor,Integrin alpha-V variant (Fragment)11 1 ITAV_HUMAN P06756
ITGB1 3688 CD29 Isoform Beta-1C of Integrin beta-1 precursor,Isoform Beta-1C-2 of Integrin beta-1 precursor,Isoform Beta-1A of Integrin beta-1 precursor,Isoform Beta-1B of Integrin beta-1 precursor,Isoform Beta-1D of Integrin beta-1 precursor,integrin beta 1 isoform 1A pr6 1 ITB1_HUMAN P05556
ITGB5 3693 na Integrin beta-5 precursor,similar to Integrin beta-5 precursor2 1 ITB5_HUMAN P18084
KALRN 8997 na Huntingtin-associated protein-interacting protein,kalirin, RhoGEF kinase isoform 1,Protein,CDNA FLJ16443 fis, clone BRAMY3004800, highly similar to Huntingtin- associated protein-interacting protein1 0 KALRN_HUMAN O60229
KIAA1546 54790 na Protein KIAA1546,Hypothetical protein Nbla00191 (Fragment)1 0 TET2_HUMAN Q6N021
KIF12 113220 na Kinesin-like protein KIF12,Kinesin family member 121 0 KIF12_HUMAN Q96FN5
KIF1B 23095 na Isoform 1 of Kinesin-like protein KIF1B,Isoform 4 of Kinesin-like protein KIF1B1 0 KIF1B_HUMAN O60333
KRT1 3848 na Keratin, type II cytoskeletal 1 9 0 K2C1_HUMAN P04264
KRT10 3858 na Keratin, type I cytoskeletal 10,57 kDa protein13 0 K1C10_HUMAN P13645
KRT2 3849 na Keratin, type II cytoskeletal 2 epidermal16 0 K22E_HUMAN P35908
KRT4 3851 na keratin 4,33 kDa protein 3 1 K2C4_HUMAN P19013
KRT5 3852 na Keratin, type II cytoskeletal 5,60 kDa protein2 0 K2C5_HUMAN P13647
KRT6A 3853 na Keratin, type II cytoskeletal 6A 1 0 K2C6A_HUMAN P02538
KRT6B 3854 na Keratin, type II cytoskeletal 6B,Keratin, type II cytoskeletal 6E,Keratin, type II cytoskeletal 6A,Keratin, type II cytoskeletal 6D (Fragment),Keratin, type II cytoskeletal 6C,18 kDa protein,Keratin 6C4 0 K2C6B_HUMAN P04259
KRT8 3856 na Keratin, type II cytoskeletal 8,25 kDa protein,14 kDa protein4 0 K2C8_HUMAN P05787
KRT9 3857 na Keratin, type I cytoskeletal 9 12 0 K1C9_HUMAN P35527
LAMC3 10319 na 172 kDa protein,Laminin, gamma 3,Laminin subunit gamma-3 precursor1 0 LAMC3_HUMAN Q9Y6N6
LAMP1 3916 CD107a lysosomal-associated membrane protein 11 1 LAMP1_HUMAN P11279
LEF1 51176 na Isoform 1 of Lymphoid enhancer-binding factor 1,Isoform 2 of Lymphoid enhancer-binding factor 1,LEF1 protein1 0 LEF1_HUMAN Q9UJU2
LEPR 3953 CD295 Isoform B of Leptin receptor precursor,Isoform A of Leptin receptor precursor,Isoform C of Leptin receptor precursor,Isoform D of Leptin receptor precursor,Isoform E of Leptin receptor precursor3 1 NCS1_HUMAN P62166
LMNA 4000 na Isoform A of Lamin-A/C,Isoform ADelta10 of Lamin-A/C,Progerin1 0 LMNA_HUMAN P02545
LOC644196 644196 na similar to CG10151-PA, isoform A1 0 na na
LOC645745 4496 na Metallothionein-1H,Metallothionein-1A,similar to Metallothionein-2,7 kDa protein1 0 na na
LRP1 4035 CD91 Low-density lipoprotein receptor-related protein 1 precursor18 1 LRP1_HUMAN Q07954
LRRC16 55604 na leucine rich repeat containing 16 1 0 LR16A_HUMAN Q5VZK9
LYST 1130 na Isoform 3 of Lysosomal-trafficking regulator,Isoform 2 of Lysosomal-trafficking regulator,Isoform 1 of Lysosomal-trafficking regulator,429 kDa protein1 0 LYST_HUMAN Q99698
M6PR 4074 na Cation-dependent mannose-6-phosphate receptor precursor,9 kDa protein1 1 MPRD_HUMAN P20645
MASP2 10747 na Isoform 1 of Mannan-binding lectin serine protease 2 precursor1 0 MASP2_HUMAN O00187
MATR3 9782 na Matrin-3,100 kDa protein 1 0 MATR3_HUMAN P43243
MRC2 9902 CD280 Macrophage mannose receptor 2 precursor1 1 MRC2_HUMAN Q9UBG0
MSN 4478 na Moesin 1 0 MOES_HUMAN P26038
MT1E 4493 na Metallothionein-1E,Metallothionein-1M1 0 MT1E_HUMAN P04732
MT1G 4495 na Isoform 1 of Metallothionein-1G,Metallothionein-1X,Metallothionein-2,Isoform 2 of Metallothionein-1G,hypothetical protein,Metallothionein-1I2 MT1G_HUMAN P13640
MTE 644314 na MTE 1 0 na na
MTRR 4552 na Isoform B of Methionine synthase reductase, mitochondrial precursor,Isoform A of Methionine synthase reductase, mitochondrial precursor1 1 ALAT1_HUMAN P24298
MTSS1 9788 na PRO1941 1 0 MTSS1_HUMAN O43312
MYBBP1A 10514 na Isoform 1 of Myb-binding protein 1A,Isoform 2 of Myb-binding protein 1A0 MBB1A_HUMAN Q9BQG0
MYEF2 50804 na Isoform 1 of Myelin expression factor 21 0 MYEF2_HUMAN Q9P2K5
NCDN 23154 na neurochondrin isoform 1,neurochondrin isoform 21 0 NCDN_HUMAN Q9UBB6
NEGR1 257194 na Neuronal growth regulator 1 precursor,NEGR1 protein5 0 NEGR1_HUMAN Q7Z3B1
NEU4 129807 na Sialidase-4,sialidase 4 1 0 NEUR4_HUMAN Q8WWR8
NID2 22795 na Nidogen-2 precursor,NID2 protein1 0 NID2_HUMAN Q14112
NOPE 57722 na HDDM36 1 1 IGDC4_HUMAN Q8TDY8
NOTCH2 4853 na Neurogenic locus notch homolog protein 2 precursor,similar to notch 2 preproprotein2 1 NOTC2_HUMAN Q04721
NOTCH3 4854 na Neurogenic locus notch homolog protein 3 precursor1 0 NOTC3_HUMAN Q9UM47
NPR2 4882 na Isoform Long of Atrial natriuretic peptide receptor B precursor,Isoform Short of Atrial natriuretic peptide receptor B precursor,30 kDa protein1 1 ANPRB_HUMAN P20594
NPR3 4883 na Isoform 1 of Atrial natriuretic peptide clearance receptor precursor,Isoform 2 of Atrial natriuretic peptide clearance receptor precursor3 1 ANPRC_HUMAN P17342
NPTN 27020 na Isoform 1 of Neuroplastin precursor,Isoform 2 of Neuroplastin precursor,Isoform 4 of Neuroplastin precursor,Isoform 3 of Neuroplastin precursor2 1 NPTN_HUMAN Q9Y639
NRP1 8829 CD304 Muscle type neuropilin 1,Isoform 1 of Neuropilin-1 precursor,Neuropilin 1,Isoform 2 of Neuropilin-1 precursor,Neuropilin 1,Neuropilin 12 NRP1_HUMAN O14786
NT5E 4907 CD73 5'-nucleotidase precursor 19 1 5NTD_HUMAN P21589
OTOF 9381 na Isoform 1 of Otoferlin 2 1 OTOF_HUMAN Q9HC10
Entrez gene 
symbol
Entrez 
Gene ID
CD 
annotation Description
Number of 
distinct 
peptides 
Assignment 
to 
membrane
UniProtKB/Swiss-
Prot ID
 UniProtKB/Swiss-
Prot AC2
P2RX4 5025 na P2X purinoceptor 4,32 kDa protein1 1 P2RX4_HUMAN Q99571
PAX2 5076 na Paired box Protein 2 isoform c 1 0 PAX2_HUMAN Q02962
PCCB 5096 na Propionyl-CoA carboxylase beta chain, mitochondrial precursor,Hypothetical protein1 0 PCCB_HUMAN P05166
PCDHGA1 56114 na Isoform 1 of Protocadherin gamma A1 precursor,Isoform 2 of Protocadherin gamma A1 precursor1 1 PCDG1_HUMAN) Q9Y5H4
PCF11 51585 na pre-mRNA cleavage complex II protein Pcf111 0 PCF11_HUMAN O94913
PDGFRB 5159 CD140b Beta platelet-derived growth factor receptor precursor1 1 PGFRB_HUMAN P09619
PHLPP 23239 na PH domain leucine-rich repeat-containing protein phosphatase1 1 ZN473_HUMAN Q8WTR7
PKD2L1 9033 na Isoform 2 of Polycystic kidney disease 2-like 1 protein1 1 PK2L1_HUMAN Q9P0L9
PKHD1L1 93035 na fibrocystin L 1 0 PKHL1_HUMAN Q86WI1
PLEKHH2 130271 na Pleckstrin homology domain-containing family H member 22 0 PKHH2_HUMAN Q8IVE3
PLXNB2 23654 na similar to Plexin-B2 precursor,similar to Plexin-B2 precursor2 1 PLXB2_HUMAN O15031
PLXND1 23129 na Isoform 1 of Plexin-D1 precursor,Isoform 2 of Plexin-D1 precursor1 1 PLXD1_HUMAN Q9Y4D7
PPAP2B 8613 na Lipid phosphate phosphohydrolase 32 1 LPP3_HUMAN O14495
PRNP 5621 CD230 Major prion protein precursor,Prion protein,Prion protein3 1 PRIO_HUMAN P04156
PSD3 23362 na Isoform 1 of PH and SEC7 domain-containing protein 3,ADP-ribosylation factor guanine nucleotide factor 6 isoform a1 0 PSD3_HUMAN Q9NYI0
PTK7 5754 na PTK7 protein tyrosine kinase 7 isoform d precursor,PTK7 protein tyrosine kinase 7 isoform c precursor,PTK7 protein tyrosine kinase 7 isoform b precursor,Transmembrane receptor PTK7-5,Tyrosine-protein kinase-like 7 precursor,112 kDa protein,PTK7 protein tyr3 1 PTK7_HUMAN Q13308
PTPRM 5797 na Receptor-type tyrosine-protein phosphatase mu precursor,157 kDa protein,164 kDa protein1 1 PTPRM_HUMAN P28827
PVRL2 5819 CD112 Isoform Delta of Poliovirus receptor-related protein 2 precursor,Isoform Alpha of Poliovirus receptor-related protein 2 precursor1 1 PVRL2_HUMAN Q92692
PVRL3 25945 CD113 Isoform 1 of Poliovirus receptor-related protein 3 precursor,CDNA FLJ90624 fis, clone PLACE1002911, weakly similar to POLIOVIRUS RECEPTOR HOMOLOG,Isoform 2 of Poliovirus receptor-related protein 3 precursor2 1 PVRL3_HUMAN Q9NQS3
QRICH2 84074 na Hypothetical protein DKFZp434P0316,CDNA FLJ25373 fis, clone TST019512 0 QRIC2_HUMAN Q9H0J4
RAC1 5879 na Isoform A of Ras-related C3 botulinum toxin substrate 1 precursor,Ras-related C3 botulinum toxin substrate 3,Isoform B of Ras-related C3 botulinum toxin substrate 1 precursor2 1 RAC1_HUMAN P63000
RAD17 5884 na Isoform 2 of Cell cycle checkpoint protein RAD17,Isoform 1 of Cell cycle checkpoint protein RAD171 0 RAD17_HUMAN O75943
RECK 8434 na Reversion-inducing cysteine-rich protein with Kazal motifs precursor18 1 RECK_HUMAN O95980
RFC1 5981 na Isoform 1 of Replication factor C subunit 1,Isoform 2 of Replication factor C subunit 11 0 RFC1_HUMAN P35251
RHOQ 23433 na 16 kDa protein 1 0 RHOQ_HUMAN P17081
RNH1 6050 na Ribonuclease inhibitor,Ribonuclease/angiogenin inhibitor1 0 RINI_HUMAN P13489
RPA3 6119 na Replication protein A 14 kDa subunit1 0 RFA3_HUMAN P35244
RPL34 6164 na 60S ribosomal protein L34 1 0 RL34_HUMAN P49207
RPS12 6206 na 40S ribosomal protein S12 1 0 JUND_HUMAN P17535
RPS3 6188 na 40S ribosomal protein S3 1 0 RS3_HUMAN P23396
SALL1 6299 na Sal-like protein 1 1 0 SALL1_HUMAN Q9NSC2
SCARF2 91179 na Scavenger receptor class F member 2 precursor,scavenger receptor class F, member 2 isoform 11 0 SREC2_HUMAN Q96GP6
SCNN1B 6338 na Isoform 1 of Amiloride-sensitive sodium channel subunit beta,Isoform 2 of Amiloride-sensitive sodium channel subunit beta,69 kDa protein,69 kDa protein1 1 SCNNB_HUMAN P51168
SELP 6403 CD62 P-selectin precursor,Selectin P,Selectin P,Selectin P,Selectin P1 1 LYAM3_HUMAN P16109
SERPINB10 5273 na Protein 1 0 SPB10_HUMAN P48595
SFRS2IP 9169 na SFRS2-interacting protein,splicing factor, arginine/serine-rich 2, interacting protein,Hypothetical protein1 0 SFRIP_HUMAN Q99590
SIAH1 6477 na Isoform 2 of E3 ubiquitin-protein ligase SIAH1,Isoform 1 of E3 ubiquitin-protein ligase SIAH1,SIAH1 protein (Fragment),33 kDa protein1 1 SIAH1_HUMAN Q8IUQ4
SLC1A4 6509 na Neutral amino acid transporter A 1 1 SATT_HUMAN P43007
SLC2A1 6513 na Solute carrier family 2, facilitated glucose transporter member 1,25 kDa protein,19 kDa protein1 1 GTR1_HUMAN P11166
SLC33A1 9197 na Acetyl-coenzyme A transporter 1 1 1 ACATN_HUMAN O00400
SLC39A14 23516 na Solute carrier family 39 member 14,SLC39A14 protein,CDNA FLJ23971 fis, clone HEP182081 1 S39AE_HUMAN Q15043
SLC3A2 6520 CD98 4F2 cell-surface antigen heavy chain,solute carrier family 3 (activators of dibasic and neutral amino acid transport), member 2 isoform a,solute carrier family 3 (activators of dibasic and neutral amino acid transport), member 2 isoform b,solute carrier fa1 1 4F2_HUMAN P08195
SLC44A1 23446 CD92 Isoform 2 of Choline transporter-like protein 1,Isoform 1 of Choline transporter-like protein 1,Isoform 3 of Choline transporter-like protein 13 1 TL1_HUMAN Q8WWI5
SLC44A2 57153 na Isoform 2 of Choline transporter-like protein 2,Isoform 1 of Choline transporter-like protein 2,CTL2 protein3 1 TL2_HUMAN Q8IWA5
SMARCD2 6603 na 54 kDa protein,SWI/SNF-related matrix-associated actin-dependent regulator of chromatin subfamily D member 2 (60 kDa BRG-1/Brm associated factor subunit B) (BRG1-associated factor 60B) (PRO2451). Splice isoform 2,Isoform 2 of SWI/SNF-related matrix-associa1 0 SMRD2_HUMAN Q92925
SNED1 25992 na SNED1 protein,similar to secreted nidogen domain protein,6720455I24Rik homolog1 0 SNED1_HUMAN Q8TER0
SORT1 6272 na Sortilin precursor 1 1 KCNK1_HUMAN O00180
SPTBN5 51332 na Spectrin beta chain, brain 4 1 0 SPTN5_HUMAN Q9NRC6
STOML3 161003 na Stomatin-like protein 3 1 1 STML3_HUMAN Q8TAV4
tcag7.350 402694 na similar to ribosomal protein L15 1 0 na na
TCEB3 6924 na Transcription elongation factor B polypeptide 31 0 ELOA1_HUMAN Q14241
TGFBR2 7048 na Isoform 1 of TGF-beta receptor type-2 precursor,Isoform 2 of TGF-beta receptor type-2 precursor1 1 TGFR2_HUMAN P37173
THBS1 7057 na Thrombospondin-1 precursor 1 0 CTGE5_HUMAN O15320
THY1 7070 CD90 Thy-1 membrane glycoprotein precursor,Thy-1 cell surface antigen variant (Fragment)1 1 THY1_HUMAN P04216
TNFRSF1B 7133 CD120b Isoform 1 of Tumor necrosis factor receptor superfamily member 1B precursor1 1 TNR1B_HUMAN P20333
TOM1L2 146691 na Target of myb1-like protein 2,Isoform 1 of TOM1-like protein 2,Isoform 2 of TOM1-like protein 21 0 TM1L2_HUMAN Q6ZVM7
TPBG 7162 na Trophoblast glycoprotein precursor5 1 MMP16_HUMAN P51512
TPM1 7168 na Isoform 1 of Tropomyosin-1 alpha chain,CDNA FLJ26372 fis, clone HRT06233,tropomyosin 1 alpha chain isoform 32 0 TPM1_HUMAN P09493
TRIM25 7706 na Tripartite motif-containing protein 251 0 TRI25_HUMAN Q14258
TSPAN14 81619 na Isoform 2 of Tetraspanin-14,Isoform 1 of Tetraspanin-14,17 kDa protein,24 kDa protein,25 kDa protein1 1 TSN14_HUMAN Q8NG11
TSPAN4 7106 na Tetraspanin-4,tetraspanin 4 isoform b1 1 TSN4_HUMAN O14817
TTC7A 57217 na Isoform 2 of Tetratricopeptide repeat protein 7A,Isoform 1 of Tetratricopeptide repeat protein 7A,TTC7A protein1 0 TTC7A_HUMAN Q9ULT0
TTN 7273 na Titin (Fragment) 1 0 TITIN_HUMAN Q8WZ42
TUBB2C 10383 na Tubulin beta-2C chain,Tubulin beta chain,Tubulin beta-2A chain,Tubulin beta-3 chain,Tubulin beta-4 chain,Tubulin beta-2B chain,Tubulin, beta, 4,50 kDa protein,Beta-tubulin 4Q,Novel protein similar to beta-tubulin 4Q,TUBB3 protein,46 kDa protein,43 kDa prot1 0 TBB2C_HUMAN P68371
TXNDC4 23071 na Thioredoxin domain-containing protein 4 precursor1 0 TXND4_HUMAN Q9BS26
UGT2B15 7366 na UDP-glucuronosyltransferase 2B15 precursor,UDP glycosyltransferase 2 family, polypeptide B15,similar to UDP-glucuronosyltransferase 2B15 precursor (UDPGT) (UDPGTh-3) (HLUG4) isoform 11 1 UDB15_HUMAN P54855
VASN 114990 na Vasorin precursor 2 1 VASN_HUMAN Q6EMK4
VCAM1 7412 CD106 Isoform 1 of Vascular cell adhesion protein 1 precursor,vascular cell adhesion molecule 1 isoform b precursor,74 kDa protein,Hypothetical protein DKFZp779G23334 1 VCAM1_HUMAN P19320
VIM 7431 na Vimentin,Vimentin,50 kDa protein2 0 VIME_HUMAN P08670
VTI1B 10490 na Isoform Long of Vesicle transport through interaction with t-SNAREs homolog 1B,Isoform Short of Vesicle transport through interaction with t-SNAREs homolog 1B,27 kDa protein1 1 VTI1B_HUMAN Q9UEU0
ZBED5 58486 na zinc finger, BED-type containing 51 0 ZBED5_HUMAN Q49AG3
ZHX3 23051 na Zinc fingers and homeoboxes protein 3,ZHX3 protein,Zinc fingers and homeoboxes 3,Zinc fingers and homeoboxes 3,Zinc fingers and homeoboxes 3,Zinc fingers and homeoboxes 3,Zinc fingers and homeoboxes 31 0 ZHX3_HUMAN Q9H4I2
ZNF417 147687 na Zinc finger protein 417 1 0 ZN417_HUMAN Q8TAU3
ZPBP2 124626 na Isoform 1 of Zona pellucida-binding protein 2 precursor,Isoform 2 of Zona pellucida-binding protein 2 precursor,36 kDa protein1 0 ZPBP2_HUMAN Q6X784
ZYX 7791 na 67 kDa protein,ZYX protein,19 kDa protein,63 kDa protein,ZYX protein,Zyxin1 1 _HUMAN Q15942
na - not assigned; 
assignment to the membrane based on predicted transmembrane domain and/or GPI-link and/or CD annotation; 
0 - not assigned, 1- assigned
Suppl.Table 3. siRNAscreen-110genes-VHR01
Genes exp1 exp2 exp3 average stdev
1 ACVR1 122.45 104.66 111.02 112.71 9.02
2 ACVR2 101.62 107.12 70.73 93.16 19.61
3 ADAM15 101.62 78.63 92.41 90.89 11.57
4 ADAM17 101.80 95.25 102.91 99.99 4.14
5 ADAM9 73.30 84.96 124.71 94.33 26.95
6 ALCAM 105.45 109.31 115.49 110.08 5.07
7 ALPL 116.49 83.10 61.75 87.11 27.59
8 ANPEP 84.76 121.65 112.25 106.22 19.17
9 ANTXR1 104.53 110.20 82.51 99.08 14.62
10 ASAM 113.72 93.30 102.54 103.18 10.23
11 BMP1 105.57 103.89 52.62 87.36 30.09
12 BMP4 101.39 72.30 66.86 80.18 18.56
13 BSG 102.91 65.81 85.51 84.74 18.56
14 CD109 138.38 96.23 109.19 114.60 21.59
15 CD151 146.47 114.53 129.54 130.18 15.98
16 CD164L1 101.57 133.15 111.32 115.34 16.17
17 CD276 80.99 119.13 85.13 95.09 20.93
18 CD44 64.90 85.29 115.35 88.51 25.38
19 CD59 70.39 108.80 97.63 92.28 19.76
20 CD63 85.31 118.25 78.34 93.97 21.32
21 CD99 108.13 104.93 70.42 94.49 20.91
22 CDC42BPA 80.14 100.84 129.80 103.59 24.94
23 CDC42BPB 73.21 104.61 135.90 104.57 31.34
24 CDGAP 102.96 106.05 132.46 113.82 16.22
25 CDH2 86.33 90.18 101.12 92.54 7.67
26 CTNNB1 78.38 65.88 87.93 77.40 11.06
27 CTSB 82.17 81.98 93.84 86.00 6.79
28 CXC12L 84.62 103.86 92.97 93.82 9.65
29 DAF 80.74 81.01 113.61 91.78 18.90
30 DKK1 99.63 86.82 85.67 90.71 7.75
31 DKK2 125.31 85.34 131.11 113.92 24.92
32 EGFR 99.03 108.10 47.05 84.73 32.94
33 EMP3 93.67 99.91 89.36 94.31 5.30
34 ENG 98.01 87.62 120.53 102.05 16.82
35 ERBB2 127.67 114.39 119.64 120.56 6.69
36 FAS 75.15 100.47 101.58 92.40 14.95
37 FAT 103.60 110.38 92.28 102.09 9.14
38 FGF2 65.06 97.81 100.37 87.75 19.69
39 FGF7 50.76 93.20 104.94 82.97 28.50
40 FGFR1 121.66 81.52 91.70 98.29 20.87
41 FN1 107.81 92.13 71.59 90.51 18.16
42 FZD6 67.48 93.02 85.11 81.87 13.07
43 FZD7 72.15 79.45 117.94 89.85 24.60
44 HSPG2 125.77 116.71 136.66 126.38 9.99
45 ICAM1 125.03 104.24 156.07 128.45 26.09
46 IGF2R 95.43 80.96 127.02 101.14 23.55
47 IL1R1 64.90 70.67 77.52 71.03 6.32
48 IL3 62.36 78.26 94.64 78.42 16.14
49 IL6 87.34 79.84 115.44 94.21 18.77
50 IL7 57.76 88.76 85.87 77.46 17.13
51 ITGA11 101.25 111.82 71.75 94.94 20.77
52 ITGA3 103.83 106.01 77.06 95.63 16.12
53 ITGA5 101.48 105.59 129.91 112.32 15.36
54 ITGAV 80.60 118.95 118.08 105.88 21.89
55 ITGB1 91.69 99.81 130.60 107.37 20.53
Genes exp1 exp2 exp3 average stdev
56 ITGB5 73.72 97.16 111.47 94.12 19.06
57 JAG1 91.36 94.69 82.76 89.61 6.16
58 JAG2 55.94 95.86 83.85 78.55 20.48
59 KITLG 88.27 87.66 100.79 92.24 7.41
60 LAMP1 76.35 75.09 83.85 78.43 4.74
61 LEPR 128.22 114.76 80.85 107.94 24.41
62 LO11C4990 107.25 134.45 103.32 115.01 16.95
63 LRP1 120.69 89.99 78.14 96.27 21.96
64 MAML1 84.02 105.17 131.84 107.01 23.96
65 MAML2 88.64 120.39 111.29 106.77 16.35
66 MAML3 87.02 110.24 128.95 108.74 21.01
67 MSN 89.79 66.71 115.16 90.55 24.23
68 NEGR1 86.37 77.98 63.23 75.86 11.72
69 NF2 98.38 93.02 98.14 96.51 3.03
70 NOTCH1 157.37 91.53 146.76 131.88 35.35
71 NOTCH2 87.71 106.05 102.83 98.86 9.79
72 NOTCH3 101.76 112.38 73.29 95.81 20.21
73 NOTCH4 74.36 88.97 78.53 80.62 7.52
74 NRP1 79.01 95.16 116.57 96.91 18.84
75 NT5E 85.13 103.21 115.25 101.20 15.16
76 P2RX4 69.12 116.81 109.29 98.41 25.64
77 PDGFRB 43.51 97.11 57.13 65.92 27.86
78 PLXNB2 72.89 70.53 84.16 75.86 7.29
79 PLXND1 63.60 78.40 103.00 81.67 19.90
80 PRNP 69.93 63.97 73.22 69.04 4.69
81 PTPRM 72.75 125.65 93.38 97.26 26.66
82 PVRL2 114.18 105.31 70.22 96.57 23.25
83 PVRL3 75.98 66.85 109.02 83.95 22.19
84 RAC1 57.83 95.34 102.73 85.30 24.08
85 RAC2 68.68 122.91 93.64 95.08 27.14
86 RAC3 72.15 92.46 84.15 82.92 10.21
87 RDX 67.85 83.52 55.05 68.81 14.26
88 RECK 70.25 106.98 76.14 84.46 19.73
89 RHOA 71.18 68.95 110.83 83.65 23.56
90 RHOB 80.65 111.69 74.72 89.02 19.85
91 RHOC 96.77 89.66 74.35 86.93 11.46
92 RHOG 114.13 86.86 59.34 86.78 27.40
93 RHOQ 65.54 106.01 68.37 79.97 22.59
94 SDFR1/NPTN 57.92 68.06 76.64 67.54 9.37
95 SMAD4 87.39 82.77 90.16 86.77 3.73
96 TGFB1 89.10 85.10 98.99 91.06 7.15
97 TGFB2 61.15 83.89 80.43 75.16 12.25
98 TGFBR1 159.77 89.80 74.89 108.15 45.32
99 TGFBR2 114.73 104.84 72.60 97.39 22.03
100 THBS1 35.52 92.18 82.72 70.14 30.35
101 THY1 132.42 137.85 75.71 115.33 34.42
102 TM4SF7 91.09 103.49 76.64 90.41 13.44
103 TPBG 51.92 83.43 75.81 70.39 16.44
104 TSLP 68.13 111.55 59.20 79.62 28.00
105 VCAM1 68.94 87.42 86.63 81.00 10.45
106 VEGF 79.31 83.10 86.13 82.85 3.42
107 VEGFC 77.92 78.58 60.18 72.23 10.44
108 VIM 98.80 85.01 65.94 83.25 16.50
109 WISP1 54.13 80.07 80.37 71.52 15.06
110 ZYX 68.73 90.50 115.18 91.47 23.24
genes selected for further validation
Suppl.Table 3. siRNAscreen-110genes-VHR01
Controls exp1 exp2 exp3
average stdev average stdev average stdev
negative controls 100 18.2455843 100 16.5077302 100 20.5954884
Positive controls 41.1188093 17.1600805 48.6809435 14.5802183 40.5695444 18.8824445
average z-factor
z-factor -0.80392063 -0.8173336 -0.99281323 -0.87135582
genes selected for further validation
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Suppl.Table 3. siRNAscreen-110genes-VHR03
Genes exp1 exp2 exp3 average stdev
1 ACVR1 166.05 76.02 136.35 126.14 45.87
2 ACVR2 69.99 85.51 91.18 82.22 10.97
3 ADAM15 35.63 12.92 61.12 36.56 24.11
4 ADAM17 148.47 91.23 121.53 120.41 28.64
5 ADAM9 142.76 74.27 76.03 97.68 39.04
6 ALCAM 121.95 74.57 95.06 97.19 23.76
7 ALPL 87.22 73.01 55.14 71.79 16.07
8 ANPEP 137.91 93.25 103.23 111.46 23.44
9 ANTXR1 87.10 71.78 63.53 74.14 11.96
10 ASAM 42.65 58.63 65.88 55.72 11.89
11 BMP1 108.78 39.31 72.08 73.39 34.76
12 BMP4 86.71 56.23 56.94 66.63 17.40
13 BSG 43.15 75.69 50.23 56.36 17.11
14 CD109 149.77 80.29 95.35 108.47 36.55
15 CD151 139.33 145.75 142.96 142.68 3.22
16 CD164L1 92.50 97.33 80.51 90.11 8.66
17 CD276 95.30 88.18 94.31 92.60 3.86
18 CD44 101.37 99.77 87.19 96.11 7.77
19 CD59 63.74 55.70 73.06 64.16 8.69
20 CD63 110.95 69.16 61.15 80.42 26.74
21 CD99 189.26 88.14 118.46 131.95 51.89
22 CDC42BPA 85.57 128.67 62.84 92.36 33.44
23 CDC42BPB 203.57 126.61 136.61 155.60 41.85
24 CDGAP 132.23 45.75 80.08 86.02 43.55
25 CDH2 100.62 24.32 68.15 64.36 38.29
26 CTNNB1 83.43 51.42 61.09 65.31 16.42
27 CTSB 91.01 54.44 68.36 71.27 18.46
28 CXC12L 108.62 85.44 72.81 88.96 18.17
29 DAF 75.71 83.11 71.50 76.77 5.88
30 DKK1 73.47 87.48 52.52 71.15 17.59
31 DKK2 54.00 101.83 56.47 70.77 26.93
32 EGFR 73.15 65.54 82.36 73.68 8.43
33 EMP3 43.10 70.87 58.05 57.34 13.90
34 ENG 99.32 61.39 64.99 75.23 20.94
35 ERBB2 93.09 116.62 68.81 92.84 23.91
36 FAS 78.55 62.52 54.53 65.20 12.23
37 FAT 78.39 94.17 89.28 87.28 8.07
38 FGF2 97.71 133.82 67.05 99.52 33.42
39 FGF7 109.21 81.93 72.66 87.93 19.00
40 FGFR1 123.29 68.05 92.30 94.55 27.69
41 FN1 47.09 38.59 66.83 50.84 14.48
42 FZD6 38.11 56.21 69.98 54.77 15.98
43 FZD7 48.96 74.00 51.78 58.25 13.72
44 HSPG2 128.96 137.32 79.82 115.37 31.07
45 ICAM1 107.48 141.94 78.33 109.25 31.84
46 IGF2R 102.59 96.61 77.58 92.26 13.06
47 IL1R1 67.08 80.79 64.35 70.74 8.81
48 IL3 98.49 125.20 76.06 99.92 24.60
49 IL6 93.57 137.36 64.13 98.35 36.85
50 IL7 79.33 93.56 38.16 70.35 28.77
51 ITGA11 79.06 130.92 64.12 91.37 35.06
52 ITGA3 45.56 124.13 33.72 67.81 49.14
53 ITGA5 39.69 129.78 32.16 67.21 54.32
54 ITGAV 97.19 101.83 61.84 86.96 21.87
55 ITGB1 91.12 175.10 62.47 109.57 58.54
Genes exp1 exp2 exp3 average stdev
56 ITGB5 44.50 124.48 36.89 68.62 48.52
57 JAG1 43.10 136.94 58.21 79.42 50.39
58 JAG2 90.49 121.73 56.78 89.67 32.48
59 KITLG 121.95 141.36 80.50 114.60 31.09
60 LAMP1 81.86 90.51 73.90 82.09 8.31
61 LEPR 110.55 30.46 75.95 72.32 40.17
62 LO11C4990 96.29 72.63 57.28 75.40 19.65
63 LRP1 45.46 70.68 57.86 58.00 12.61
64 MAML1 132.35 128.97 85.58 115.63 26.08
65 MAML2 164.71 106.10 116.15 128.99 31.34
66 MAML3 105.75 114.64 74.88 98.42 20.87
67 MSN 89.88 114.83 60.88 88.53 27.00
68 NEGR1 63.26 118.41 60.43 80.70 32.69
69 NF2 115.48 64.24 69.25 82.99 28.25
70 NOTCH1 132.39 56.35 81.24 89.99 38.77
71 NOTCH2 73.15 89.86 53.57 72.19 18.17
72 NOTCH3 65.54 74.95 46.23 62.24 14.64
73 NOTCH4 33.05 70.75 54.23 52.67 18.90
74 NRP1 99.91 73.85 80.51 84.76 13.54
75 NT5E 82.18 91.27 61.00 78.15 15.53
76 P2RX4 63.10 89.55 75.08 75.91 13.25
77 PDGFRB 52.67 82.58 78.40 71.22 16.19
78 PLXNB2 81.98 72.52 64.43 72.98 8.78
79 PLXND1 101.33 44.87 71.61 72.61 28.24
80 PRNP 107.60 44.53 95.53 82.55 33.48
81 PTPRM 64.32 60.98 79.72 68.34 9.99
82 PVRL2 68.22 70.07 54.91 64.40 8.27
83 PVRL3 69.84 58.19 46.17 58.07 11.83
84 RAC1 43.75 92.64 89.50 75.30 27.37
85 RAC2 66.25 117.69 59.05 81.00 31.98
86 RAC3 91.48 97.98 96.48 95.31 3.40
87 RDX 75.67 99.39 92.45 89.17 12.19
88 RECK 68.86 133.78 51.63 84.75 43.32
89 RHOA 77.88 133.66 55.89 89.14 40.09
90 RHOB 66.73 65.61 85.14 72.49 10.96
91 RHOC 70.08 64.22 93.17 75.82 15.31
92 RHOG 84.60 54.78 84.57 74.65 17.21
93 RHOQ 67.75 63.36 72.22 67.78 4.43
94 SDFR1/NPTN 81.99 110.26 43.88 78.71 33.31
95 SMAD4 97.08 44.13 75.43 72.21 26.62
96 TGFB1 114.38 52.80 87.62 84.93 30.88
97 TGFB2 87.81 43.92 67.61 66.45 21.97
98 TGFBR1 24.50 38.70 68.99 44.06 22.72
99 TGFBR2 107.13 102.21 85.85 98.40 11.14
100 THBS1 81.98 46.88 60.26 63.04 17.71
101 THY1 72.48 58.56 87.13 72.72 14.29
102 TM4SF7 53.21 72.61 77.03 67.62 12.67
103 TPBG 39.13 49.60 62.56 50.43 11.74
104 TSLP 54.11 48.08 63.51 55.23 7.77
105 VCAM1 53.33 75.49 60.57 63.13 11.30
106 VEGF 57.74 64.75 83.30 68.60 13.21
107 VEGFC 44.71 55.10 27.73 42.51 13.82
108 VIM 91.37 63.76 74.53 76.56 13.92
109 WISP1 63.61 72.38 51.88 62.62 10.29
110 ZYX 53.80 85.23 93.15 77.39 20.81
genes selected for further validation
Suppl.Table 3. siRNAscreen-110genes-VHR03
Controls exp1 exp2 exp3
average stdev average stdev average stdev
negative controls 100 18.9088129 100 18.0694055 100 19.2847865
Positive controls 3.44430431 5.56674795 4.30169018 7.19665348 13.6904196 7.8478652
average z-factor
z-factor 0.23954064 0.20794655 0.05690707 0.16813142
genes selected for further validation
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Suppl.Table 3. siRNAscreen-110genes-VHR04
Genes exp1 exp2 exp3 average stdev
1 ACVR1 156.92 185.84 143.21 161.99 21.77
2 ACVR2 85.64 87.85 118.04 97.17 18.10
3 ADAM15 85.77 90.04 117.41 97.74 17.17
4 ADAM17 134.37 125.93 94.10 118.13 21.24
5 ADAM9 108.95 79.03 116.79 101.59 19.93
6 ALCAM 108.33 103.19 142.19 117.91 21.19
7 ALPL 81.35 120.21 112.31 104.62 20.54
8 ANPEP 108.10 71.35 122.43 100.63 26.34
9 ANTXR1 97.49 72.12 110.76 93.45 19.63
10 ASAM 93.32 137.13 106.31 112.26 22.50
11 BMP1 117.45 131.12 128.07 125.55 7.18
12 BMP4 93.58 131.32 135.32 120.07 23.03
13 BSG 43.50 72.81 74.42 63.58 17.41
14 CD109 132.69 114.20 72.39 106.43 30.89
15 CD151 135.03 129.41 89.02 117.82 25.10
16 CD164L1 111.33 114.49 78.01 101.27 20.21
17 CD276 107.19 113.92 114.28 111.80 3.99
18 CD44 122.10 78.74 58.30 86.38 32.58
19 CD59 122.27 117.06 141.32 126.89 12.77
20 CD63 115.59 130.98 139.94 128.84 12.32
21 CD99 95.34 149.48 130.85 125.22 27.50
22 CDC42BPA 87.34 100.14 115.62 101.04 14.16
23 CDC42BPB 47.22 62.19 79.17 62.86 15.98
24 CDGAP 107.97 114.87 47.56 90.13 37.03
25 CDH2 80.13 92.72 59.29 77.38 16.88
26 CTNNB1 82.87 101.81 73.56 86.08 14.40
27 CTSB 82.84 90.12 71.35 81.44 9.47
28 CXC12L 103.61 91.66 99.05 98.11 6.03
29 DAF 121.13 61.82 56.96 79.97 35.73
30 DKK1 87.33 57.82 109.98 85.04 26.16
31 DKK2 111.23 134.80 101.29 115.78 17.21
32 EGFR 111.49 124.93 123.95 120.12 7.49
33 EMP3 88.76 117.59 90.45 98.94 16.18
34 ENG 99.57 94.52 87.26 93.78 6.19
35 ERBB2 123.11 111.34 71.83 102.09 26.87
36 FAS 55.61 70.02 43.91 56.52 13.08
37 FAT 70.85 124.59 108.37 101.27 27.56
38 FGF2 119.40 122.16 34.12 91.90 50.05
39 FGF7 97.00 118.59 101.92 105.84 11.32
40 FGFR1 111.36 98.24 116.61 108.73 9.46
41 FN1 76.39 129.89 63.14 89.80 35.34
42 FZD6 81.92 68.62 53.59 68.04 14.18
43 FZD7 56.98 95.28 41.14 64.47 27.84
44 HSPG2 71.65 124.21 46.84 80.90 39.51
45 ICAM1 107.06 148.38 68.51 107.98 39.94
46 IGF2R 95.08 77.96 41.14 71.39 27.56
47 IL1R1 79.71 78.32 65.74 74.59 7.70
48 IL3 116.41 133.98 82.13 110.84 26.37
49 IL6 106.45 111.44 108.01 108.63 2.55
50 IL7 87.39 74.59 112.34 91.44 19.20
51 ITGA11 129.14 164.01 147.32 146.83 17.44
52 ITGA3 133.15 112.20 41.56 95.63 47.99
53 ITGA5 82.05 112.58 48.99 81.21 31.81
54 ITGAV 85.05 89.42 64.12 79.53 13.52
55 ITGB1 94.10 123.69 86.07 101.29 19.81
Genes exp1 exp2 exp3 average stdev
56 ITGB5 81.31 95.19 76.75 84.42 9.60
57 JAG1 68.35 101.67 123.68 97.90 27.86
58 JAG2 113.22 112.35 73.35 99.64 22.77
59 KITLG 140.27 114.44 67.80 107.50 36.73
60 LAMP1 64.73 99.81 43.71 69.42 28.34
61 LEPR 98.82 128.55 104.69 110.69 15.74
62 LO11C4990 90.36 78.07 85.08 84.50 6.16
63 LRP1 82.35 103.19 104.96 96.83 12.58
64 MAML1 111.59 120.02 145.18 125.59 17.47
65 MAML2 112.24 104.91 102.37 106.50 5.13
66 MAML3 115.72 125.02 72.63 104.46 27.95
67 MSN 71.02 104.39 43.26 72.89 30.61
68 NEGR1 90.00 89.18 49.17 76.12 23.34
69 NF2 108.85 134.80 61.26 101.64 37.30
70 NOTCH1 107.16 75.12 64.12 82.13 22.36
71 NOTCH2 163.82 94.04 125.11 127.66 34.96
72 NOTCH3 126.99 124.26 75.68 108.98 28.87
73 NOTCH4 73.25 92.09 49.35 71.56 21.42
74 NRP1 90.10 98.81 69.32 86.07 15.15
75 NT5E 120.61 118.21 48.27 95.70 41.09
76 P2RX4 95.40 85.89 40.30 73.87 29.45
77 PDGFRB 78.44 80.51 66.01 74.98 7.84
78 PLXNB2 98.56 56.29 63.23 72.69 22.67
79 PLXND1 97.94 75.21 67.62 80.26 15.78
80 PRNP 128.06 67.64 120.64 105.45 32.95
81 PTPRM 96.64 164.73 171.15 144.17 41.29
82 PVRL2 110.58 139.28 74.24 108.03 32.59
83 PVRL3 106.93 107.20 76.84 96.99 17.45
84 RAC1 111.88 78.36 81.86 90.70 18.43
85 RAC2 112.76 106.34 54.81 91.30 31.77
86 RAC3 64.33 80.22 44.72 63.09 17.78
87 RDX 102.11 85.65 55.44 81.07 23.67
88 RECK 108.17 74.30 83.29 88.59 17.54
89 RHOA 151.31 62.58 106.13 106.67 44.37
90 RHOB 78.44 58.58 134.52 90.51 39.38
91 RHOC 100.13 98.14 156.37 118.21 33.06
92 RHOG 111.33 147.71 130.13 129.72 18.20
93 RHOQ 79.78 137.70 86.51 101.33 31.68
94 SDFR1/NPTN 71.39 76.07 69.20 72.22 3.51
95 SMAD4 91.11 96.47 56.87 81.48 21.48
96 TGFB1 102.63 90.75 94.31 95.90 6.10
97 TGFB2 75.51 86.70 75.95 79.39 6.34
98 TGFBR1 74.37 189.47 109.35 124.40 59.00
99 TGFBR2 89.15 126.88 100.49 105.51 19.36
100 THBS1 73.95 133.65 65.92 91.17 37.01
101 THY1 73.39 239.28 204.55 172.41 87.49
102 TM4SF7 102.18 128.46 79.26 103.30 24.62
103 TPBG 87.33 117.25 93.86 99.48 15.73
104 TSLP 59.55 124.83 63.95 82.78 36.49
105 VCAM1 81.01 82.46 50.87 71.45 17.84
106 VEGF 90.27 86.56 65.11 80.65 13.58
107 VEGFC 98.99 83.08 88.57 90.22 8.08
108 VIM 76.81 143.99 81.14 100.65 37.60
109 WISP1 62.58 123.16 96.54 94.10 30.37
110 ZYX 103.90 226.17 147.50 159.19 61.96
genes selected for further validation
Suppl.Table 3. siRNAscreen-110genes-VHR04
Controls exp1 exp2 exp3
average stdev average stdev average stdev
negative controls 100 18.6370431 100 20.2749048 100 20.8932595
Positive controls 2.73695856 3.06858677 3.52981676 2.7867565 22.8077403 8.22121568
average z-factor
z-factor 0.33050737 0.28283557 -0.13150497 0.16061266
genes selected for further validation
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